Stem cell-derived human microglial cells, methods of making and methods of use
By activating and inhibiting Wnt signaling and using pro-hematopoietic cytokines, stem cells are differentiated into microglial cells that accurately replicate human microglia, addressing the developmental gap in existing methods and facilitating disease modeling and treatment.
Patent Information
- Application Number
- JP2024135630
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-09-28
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for generating human microglial cells in vitro do not follow the developmental paradigm of primary hematopoiesis and fail to accurately replicate human microglia, making disease modeling and treatment challenging due to the lack of early yolk sac precursor-derived cells.
A method involving Wnt signaling activation and inhibition, combined with pro-hematopoietic cytokines, is used to differentiate stem cells into microglial cells by mimicking primary hematopoiesis, followed by co-culture with neurons to achieve microglial markers, ensuring developmental accuracy.
The method generates microglial cells that express key human microglial genes and functional markers, enabling effective disease modeling and potential therapeutic applications for neurodevelopmental and neurodegenerative diseases.
Smart Images

Figure 2024164081000005 
Figure 2024164081000006 
Figure 2024164081000007
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 738,176, filed Sep. 28, 2018, the contents of which are incorporated herein by reference in their entirety and priority is claimed. Introduction
[0002] The present disclosure relates to methods for generating microglial cells derived from stem cells (e.g., human stem cells), microglial cells obtained from such methods as well as compositions comprising same, and uses of such microglial cells for disease modeling and treating microglia-associated disorders. [Background technology]
[0003] Microglia (i.e., microglial cells) are tissue-resident macrophages of the central nervous system (CNS) that colonize the brain during early embryonic development (Prinz et al., Nat. Rev. Neurosci. (2014); 15, 300-312). These phagocytes are involved in many roles in the CNS, including removal of cellular debris, signaling to neurons and astrocytes to mediate synaptic connections, and maintaining CNS homeostasis. The current literature on microglial biology has only been explored in rodent models (Bechade et al., Front Cell Neurosci. (2013); 7, 32;Bialas et al., Nat. Neurosci. (2013); 16, 1773-1782;Bilimoria et al., Brain Res. (2015); 1617, 7-17;Ji et al., PLoS One (2013); 8; 48;Pascual et al., Proc. Natl. Acad. Sci. (2012);109;Schafer et al., Neuron (2012); 74, 691-705;Tremblay et al. PLoS Biol. (2010); 8;Wu et al., Trends Immunol. (2015);36, 605-613;Zhan et al. Nat. Neurosci. (2014); 17, 400-406).
[0004] Although mice are a powerful mammalian system for showing parallels to human pathologies, notable differences exist between mouse and human microglia (Zhang et al., Neuron (2016); 89, 37-53). These include basal receptors that are expressed only in mice but not in humans, such as the macrophage F4 / 80 receptor, as well as functional differences in response to drug treatment (Smith et al., Trends Neurosci. (2014); 37, 125-135). Furthermore, certain neurodevelopmental diseases are strongly associated with genes that are not expressed in mice, such as schizophrenia, which is associated with the complement component C4A allele (Havik et al., Biol. Psychiatry (2012); 70, 35-42; Sekar et al., Nature (2016);530, 177-183). However, primary human microglia are expensive, difficult to obtain from post-mortem tissue, and do not grow in culture, making disease modeling extremely difficult (Melief et al., Glia. (2016); 64(11):1857-681). Alternative immortalized human microglial cell lines do not share key genes with primary microglia (Melief et al., Glia. (2016); 64(11):1857-681).
[0005] Human pluripotent stem cell (i.e., hPSC)-derived microglia allow for the provision of microglia developmentally derived from a patient's cells, which have the same functions as microglia found in the patient's brain. hPSCs are self-renewing cells derived from human embryonic stem cells (i.e., ES cells) or induced pluripotent stem cells (i.e., iPS cells) and have the ability to differentiate into any cell type in the body. Typically, iPS cells are derived from somatic cells of an individual affected by a particular disease. hPSC-derived microglia can be used to explore non-cell-autonomous interactions between neurons and microglia when modeling diseases, and these can be used to screen potential drug targets (Hoing et al., Cell Stem Cell (2012);11, 620-632). Furthermore, hPSC-derived microglia can be used as a potential cell therapy for neurodevelopmental and neurodegenerative diseases, as well as CNS brain tumors.
[0006] Microglia are the only tissue-resident macrophages that arise directly from yolk sac precursors, whereas others arise from precursors that first migrate to the liver (Hoeffel et al., Immunity (2015); 42, 665-678). As a result, it is important to generate microglia by modeling early yolk sac primitive hematopoiesis. Existing strategies for generating human microglia in vitro do not follow this developmental paradigm and fail to first initiate primary hematopoiesis. These strategies either initiate microglia from peripheral monocytes that arise from definitive hematopoiesis and thus cannot be obtained in vivo (Noto et al., 2013). et al., Neuropathol. Appl. Neurobiol. (2014); 40, 697-713;Ohgidani et al., Sci. Rep. (2014); 4, 4957), or by using embryoid body approaches that are not prepatterned with respect to primary hematopoiesis and are therefore a black box with respect to developmental cell fate decisions (Etemad et al., Neurosci. (2012); 209, 79-89;Hinze et al., Inflamm. (2012); 9, 12;Lachmann et al., Stem Cell Reports (2015);4, 282-296;Noto et al., Neuropathol. Appl. Neurobiol. (2014); 40, 697-713;Ohgidani et al., Sci. Rep. (2014); 4, 4957;van Wilgenburg et al., PLoS One (2013); 8.;Muffat et al., Nature Medicine (2016); 22(11), 1358-1367;Bahrini et al., Sci. Rep. (2015);5, 7989). It is difficult to determine whether these strategies are via early erythromyeloid progenitors (EMPs), which are the true precursors of microglia, or via later EMPs that lead to definitive hematopoiesis. Thus, novel methods for generating human microglial cells are needed. [Prior art documents] [Non-patent literature]
[0007] [Non-Patent Document 1] Bechade et al., Front Cell Neurosci. (2013); 7, 32 [Non-Patent Document 2] Bialas et al., Nat. Neurosci. (2013); 16, 1773-1782 [Non-Patent Document 3] Bilimoria et al., Brain Res. (2015); 1617, 7-17;Ji et al., PLoS One (2013); 8; 48 [Non-Patent Document 4] Pascual et al., Proc. Natl. Acad. Sci. (2012);109 [Non-Patent Document 5] Schafer et al., Neuron (2012); 74, 691-705;Tremblay et al. PLoS Biol. (2010); 8 [Non-Patent Document 6] Wu et al., Trends Immunol. (2015);36, 605-613 [Non-Patent Document 7] Zhan et al. Nat. Neurosci. (2014); 17, 400-406 [Brief description of the drawings]
[0008] [Figure 1-1] 1A and 1B illustrate a differentiation method according to certain embodiments of the present disclosure. FIG. 1A shows a combination of Wnt inhibition and activation that resulted in KDR+CD235a+ double positive primary hematopoietic precursors. Activation of Wnt with the Wnt agonist Chir099021 for 18 hours resulted in early mesoderm characterized by brachyury (T) by immunofluorescence. These cells were also KDR+ and CD235a+ (primary hematopoietic precursors) by day 4 of differentiation by flow cytometry. FIG. 1B shows the timing of ChiR exposure. The concentration and timing of Chir099021 exposure in the differentiation scheme was optimized, with 18 hours of exposure at 3 μM followed by Wnt inhibition via IWP2 at 3 μM resulting in the highest percentage of primary hematopoietic precursors (KDR+CD235a+) by flow cytometry. [Figure 1-2] Same as above.
[0009] [Diagram 2]Figure 2 shows the timeline of hemogenic endothelial cell and hematopoietic cell development. Hematopoietic endothelial cells developed 1 day after reseeding sorted KDR+CD235a+ primary hematopoietic progenitors. These cells gave rise to hematopoietic cells in suspension over 7 days in culture, which gradually expanded in culture.
[0010] [Diagram 3] Figure 3 shows validation of hemogenic endothelial cells by VE-cadherin+ staining. One day after sorting, cells were positive for VE-cadherin by immunofluorescence, confirming that they were hemogenic endothelial cells, and the cells in suspension had small nuclei characteristic of hematopoietic cells.
[0011] [Figure 4] Figure 4 shows round cell cultures that progressed through developmental intermediates: Kit+, Kit+CD45+. Five days after reseeding, primary hematopoietic progenitor Kit+ cells emerged, which were early erythromyeloid precursors (EMPs), precursors to microglia. These cells then reached CD45+ by flow cytometry, indicating that hematopoietic commitment was complete.
[0012] [Diagram 5] Figure 5 shows the strategy for deriving hPSC-microglia. From the EMP stage, microglia can be derived by either directly co-culturing with neurons for at least 4 days or by maturing them separately into macrophages and then co-culturing with neurons for at least 11 days.
[0013] [Figure 6]Figure 6 shows macrophage markers (round cells, progenitors) present in a small subset of EMP / pMac. Eight days after sorting the cultures, when a mixed population of EMPs was present, these cells were identified as microglia and macrophage precursors, not mature macrophages. Only a small percentage of macrophages expressed mature macrophage markers, such as CX3CR1, CD14, Cd11b, and MRC. The majority of cells expressed CD45, indicating that they were committed to the hematopoietic lineage. All markers were confirmed by flow cytometry.
[0014] [Figure 7] Figure 7 shows that culturing pMacs with neurons resulted in Iba1+Pu.1+ cells by day 4 of co-culture. Culturing cells in suspension with pMacs with neurons, 8 days after sorting, resulted in early microglial cells by only day 4 of co-culture. These cells were identified using Iba1+ and Pu.1+ staining. All cells that were CD45+ were also Pu.1+, indicating that any hematopoietic cells (represented by CD45+) that persisted in the culture were committed to the myeloid / microglial lineage (represented by PU.1). This shows that this strategy by immunofluorescence is highly efficient.
[0015] [Figure 8] Figure 8 shows that Iba1+ cells were stable in culture. Microglial cells (Iba1+ by immunofluorescence) remained persistent in the co-cultures 14 days after co-culture with cortical neurons.
[0016] [Figure 9] Figure 9 shows that Iba1+ cells were stable in culture. Microglial cells (Iba1+, PU.1+ by immunofluorescence) remained persistent in co-culture with neurons after 21 days in culture.
[0017] [Figure 10]Figure 10 shows cultured pMacs in RPMI + 10% serum, M-CSF, IL-34. In a second strategy to generate microglia, EMPs were matured into macrophages with 10% serum and M-CSF and IL-34. They developed mature macrophage marker CD11b by day 4 in culture and mature spindle morphology by day 11.
[0018] [Figure 11] Figure 11 shows efficient induction of macrophages detected using macrophage markers present on the majority of cells after 11 days indicative of mature macrophages. All cells sustained in culture in serum and M-CSF and IL-34 after 11 days were CD45+, indicating that they were all hematopoietic. Most were also positive for mature macrophage markers such as CX3CR1, CD14, CD11b, and Dectin by flow cytometry analysis.
[0019] [Figure 12] Figure 12 provides a serum-free method for pMacs cultured in IMDM / F12 / N2 / B27+M-CSF, IL-34. pMacs can also be matured to macrophages without serum using IMDM / F12 / N2 / B27 instead of serum and M-CSF and IL-34. Addition of IL-34 to M-CSF increased yields by promoting cell division. Addition of GM-CSF caused cells to divide similarly, but the resulting cells appeared more granular and activated.
[0020] [Figure 13]Figure 13 shows that co-culture of macrophage-like cells with neurons shows strong Iba1 and Pu.1 expression. Co-culture of macrophage cells with neurons resulted in microglial cells with branched morphology and increased Iba1 immunofluorescence staining. Since Iba1 was increased in microglial cells from macrophages, the cells were transitioning to a microglial identity through co-culture with neurons.
[0021] [Figure 14] Figure 14 shows that co-cultured pMac-derived microglia (EMP co-cultures) and pMac-macrophage-derived microglia (EMP-macrophage co-cultures) share expression of key microglial genes with human fetal microglia. Quantitative PCR of RNA from two different strategies to derive microglia shared gene expression of a panel of key microglial genes with RNA from human fetal microglia (a commercial source). In contrast, monocyte-derived macrophages, which represent peripheral macrophages, did not express these markers. Notably, when EMP-derived macrophages were cultured alone, they downregulated the key microglial genes TMEM119 and SALL1, indicating that co-culture was required to maintain microglial identity.
[0022] [Figure 15] Figure 15 shows day 14 chick cultures of neurons, microglia and astrocytes. Microglial cells from the present disclosure can be co-cultured with astrocytes to create a system containing three components of the CNS: neurons, microglia, and astrocytes. Microglia were tagged with RFP and astrocytes with GFAP+ by immunofluorescence.
[0023] [Figure 16]Figure 16 shows day 30 chick cultures of neurons, microglia and astrocytes. Microglial cells from the present disclosure can be co-cultured with astrocytes to create a system containing three components of the CNS: neurons, microglia, and astrocytes. Microglia were tagged with RFP and astrocytes with GFAP+ by immunofluorescence.
[0024] [Figure 17] FIG. 17 shows a avian culture system that can be used to study interactions between cell types. Inflammatory stimuli, or disease conditions that induce inflammatory stimuli, affect both microglia and astrocytes, which have a crosstalk. This crosstalk is a feedback or feed-forward loop that can subsequently result in toxicity to neurons. This interaction can be studied using the hPSC-derived microglia disclosed herein in avian cultures with hPSC-derived astrocytes and neurons to explore a fully human system in vitro.
[0025] [Figure 18]Figure 18 shows that LPS stimulation in avian cultures resulted in the release of reactive cytokines. 1 μg / mL LPS was added to cells in avian cultures containing microglia, astrocytes, and neurons, or to cultures containing only microglia and neurons, or only astrocytes and neurons, or only neurons. Since microglia was the only cell type expressing the receptor for LPS (TLR4), only cultures containing it responded to LPS, but avian cultures had increased release of C3 compared to cultures with only microglia and neurons. The effect may be due to reactive cytokines from activated microglia feeding back to astrocytes, resulting in their reactivity and the release of astrocytic C3. LPS-stimulated avian and microglia / neuron-only cultures also secreted other reactive cytokines, including IL-6, TNFα, GM-CSF, IL1B, and IFNγ. Cytokines were measured via ELISA.
[0026] [Figure 19] FIG. 19 shows that avian cultures containing Alzheimer's neurons showed increased C3 enhancement and C3 release compared to H9 controls. Avian cultures co-cultured with APP / SWe mutant neurons, a genetic model for familial Alzheimer's disease, showed increased C3 compared to cultures with microglia and neurons only, and levels were increased compared to cultures in which neurons were derived from the H9 control embryonic stem cell line. In contrast, C3 levels were not increased in avian cultures compared to microglia / neuron cultures in the H9 control, indicating that C3 enhancement did not occur without disease stimulation. C3 was measured via ELISA.
[0027] [Figure 20]Figure 20 shows that GM-CSF reduced C3 release in both Alzheimer's and H9 co-cultures. GM-CSF reduced C3 release in all cultures, both Alzheimer's and control. Cell counts by immunofluorescence were also comparable between GM-CSF and control conditions, indicating that this effect was not due to a reduction in microglial cells.
[0028] [Figure 21] Figure 21 shows that amyloid-β burden was reduced in microglial co-cultures with selectivity for amyloid-42 peptide. Co-cultures of microglial cells with Alzheimer's neurons showed a reduction in total amyloid beta via ELISA, and specifically a reduction in amyloid-beta 42 peptide when compared to the 40 and 38 peptides.
[0029] [Figure 22] Figure 22 shows that the increase in fluorescence of 42-488 inside microglial cells indicated increased uptake. To assay whether microglial cells phagocytose amyloid-beta, we used fluorescently labeled amyloid-beta 42 peptide with Alexa Fluor 4888, and found by immunofluorescence that after 2 hours, the majority of microglial cells contained amyloid-beta 42 within them. Meanwhile, amyloid-beta 40 (labeled by 555) was not found as brightly within microglial cells, indicating that it was not phagocytosed as efficiently. This demonstrated selectivity for amyloid-beta 42 by microglial cells.
[0030] [Figure 23]Figure 23 shows that switching the fluorophore gave similar results, with amyloid-beta 42 taken up to a greater extent by microglial cells. Switching the fluorophores representing amyloid 42 and 40 ensured that the effect of increased brightness of 42 in the cells was not due to an effect of technical fluorophore brightness. Even with the switched fluorophores, 42 was still labeled at 555 and 40 at 488 in this experiment, but there was still more brightness of 42 present in the microglial cells by immunofluorescence, confirming previous results that microglial cells selectively phagocytosed amyloid-beta 42.
[0031] [Figure 24] Figure 24 provides FACS analysis showing selectivity for amyloid-42 at baseline and increased uptake upon GM-CSF treatment. GM-CSF treatment increased phagocytosis of amyloid-beta 42 and 40 in microglial cells, and the number of cells with amyloid-beta peptide in them was quantified using flow cytometry.
[0032] [Diagram 25] Figure 25 shows that ALS microglia and astrocytes increased complement C3 release at baseline. SOD1 mutant iPSC-derived ALS astrocytes and microglia were cultured alone or together and showed higher C3 levels relative to syngeneic wild-type control cell line-derived astrocytes or microglia quantified by ELISA. This indicates that C3 reactivity is not specific to Alzheimer's and that the system disclosed here can also be used to study other neurodegenerative diseases where loops between microglia, astrocytes, and neurons likely exist.
[0033] [Figure 26-1]Figures 26A-26D show that patterning towards primary hematopoiesis occurred during a narrow developmental window. Figure 26A shows a schematic of an exemplary presently disclosed method for differentiating primary hematopoietic cells from hPSCs. Figure 26B shows that WNT inhibition must begin 18 hours after WNT activation to effectively generate KDR+CD235A+ hemangioblasts. Figure 26C shows that optimized WNT activation followed by inhibition generated a 30% KDR+CD235A+ population by day 3. Figure 26D shows that only the KDR+CD235A+ fraction produced CD43+CD235A+CD41+EMPs by day 6 and CD45+macrophage precursors by day 10 of differentiation. [Figure 26-2] Same as above.
[0034] [Figure 27-1]Figures 27A-27F show that single-cell RNA sequencing demonstrated stages of microglial development within in vitro differentiation. Figure 27A shows that T-distributed stochastic neighbor embedding (TSNE) following diffusion mapping of integrated data from day 6 and day 10 cultures reveals distinct hemogenic endothelial (HE), erythromyeloid precursor (EMP), erythroid (ERY), megakaryocyte (MK), and early macrophage (PMAC) clusters. Figure 27B shows Palantir analysis showing that the HE cluster is the least differentiated, progressing through an EMP intermediate and bifurcating towards three distinct differentiation trajectories of erythroid (ERY), megakaryocyte (MK), and myeloid (MY) populations over pseudotime. Figure 27C shows that the distinct differentiation arms (ERY, MK, and MY) progressively expressed key markers of ERY, MK, and MY identity over pseudotime. Figure 27D shows a heatmap of gene expression data from cells along the myeloid trajectory across pseudotime compared to mouse yolk sac EMP and PMAC gene signatures (Mass et al., Science (2016); 353(6304) aaf4238), showing that for EMP genes corresponding to the human EMP cluster in vitro, abundance is between 0.16 and 0.77 pseudotimes, and for PMAC genes corresponding to the human PMAC cluster in vitro, abundance is between 0.8 and 1.0 pseudotimes. Figure 27E provides mapping of the human in vitro data to mouse gastrulation data showing similarities between the human PMAC cluster and the mouse My (myeloid) cluster. Figure 27F shows the human pMAC cluster in vitro that most closely maps with the cluster present during E8.5 of mouse development. [Figure 27-2] Same as above. [Figure 27-3] Same as above.
[0035] [Figure 28-1]Figures 28A-28J show two different methods for deriving hPSC-microglia from the PMAC stage that are molecularly and functionally similar to in vivo microglia. Figure 28A shows a schematic diagram for the two methods for deriving microglia from the PMAC. Figure 28B shows that direct co-culture of day 10 precursors with hPSC-derived cortical neurons yielded ramified IBA1+ cells by day 4 of co-culture. Figure 28C shows that in the co-culture, more than 30% of the cells expressed CX3CR1+ at day 4 of co-culture. Figure 28D shows that GFP+ day 10 precursors co-cultured with hPSC-derived cortical neurons for 6 days were more than 50% CD45+, of which more than 80% were CX3CR1+. The GFP+ population, which is CD45-negative (CD45-), consisted of about 50% CD41+CD235A+ (EMP), and about 50% were uncommitted. FIG. 28E shows that maturation of day 10 precursors in neuron-free IL-34 and M-CSF results in a progressively purer population of primitive macrophages expressing CD11B (~99%) and CX3CR1 (>85%) by day 11 in culture. PBMCs matured in parallel express CD11B (100%) but not CX3CR1+. FIG. 28F shows that culturing primitive macrophages with hPSC-derived cortical neurons resulted in ramified IBA1+ microglia-like cells. FIG. 28G shows that co-cultured microglial cells maintained expression of CX3CR1, expressed lower CD45 and upregulated key microglia-specific genes than PBMC-matured macrophages co-cultured with cortical neurons, did not express CX3CR1, and had higher CD45 expression. Figure 28H shows that hPSC-microglia generated from either method expressed a key panel of microglia-specific genes similar to human fetal microglia (RNA from commercial source), whereas PBMC-derived macrophages did not. Expression of TMEM119 and SALL1 was increased in co-cultures compared to microglia cultured alone. n=2. Figure 28I shows gene expression of bulk RNA-sequencing data of adult microglia derived from two different methods. n=3 per group.FIG. 28J shows confocal imaging (40×) of microglia co-cultured with d70 hPSC-derived cortical neurons containing inclusions of synaptic proteins (panel i); quantification of inclusions containing general neuronal material labeled with RFP showed that they were larger in volume than inclusions containing synaptic proteins (panel ii). n=4 per group. [Figure 28-2] Same as above. [Figure 28-3] Same as above. [Figure 28-4] Same as above. [Figure 28-5] Same as above. [Figure 28-6] Same as above.
[0036] [Figure 29-1]Figures 29A-29K show that hPSC-derived microglia cultured with hPSC-derived astrocytes and neurons establish a functional human avian culture system that allows modeling of the neuroinflammatory axis in vivo. Figure 29A shows a schematic of avian culture differentiation. Figure 29B shows that hPSC-derived astrocytes were GFAP+ and some were AQP4+. Figure 29C shows that hPSC-derived neurons were telencephalic and maintained FOXG1. Figure 29D shows that D50 hPSC-derived neurons expressed the cortical layer markers TBR1 and CTIP2. Figure 29E represents avian cultures showing IBA1+ microglia and GFAP+ astrocytes that interacted with MAP2+ neurons. Figure 29F represents avian cultures with minimal cell death as measured by CC3+. FIG. 29G shows that C3 protein secretion was increased in tric cultures (TRI) compared to microglia / neuron (M / N) cultures, which deteriorated upon LPS treatment, as measured by ELISA. No C3 was secreted in astrocyte / neuron (A / N) and neuron only (N) cultures. n=4 per group, ANOVA, Sidak's post-hoc test. FIG. 29H shows that LPS stimulation induced secretion of other inflammatory cytokines. FIG. 29I shows that C3 KO microglia did not secrete C3 protein by ELISA. FIG. 29J shows that C3KOA cultures had reduced C3 release compared to wild-type (wt) tric cultures, but secreted more C3 than M / N cultures. C3KOM cultures had lower minimal C3 release levels. C3 release in C3KOA cultures was reduced by LPS treatment compared to tric cultures; C3KOM released less C3 compared to other groups. FIG. 29K shows a neuroinflammatory loop in chick cultures initiated by microglial signaling to astrocytes, which signaled back to microglia to increase C3 release. [Figure 29-2] Same as above. [Figure 29-3] Same as above. [Figure 29-4] Same as above. [Figure 29-5] Same as above.
[0037] [Figure 30-1] Figures 30A-30H illustrate that Alzheimer's disease (AD) avian culture models showed increased C3 release in AD avian cultures caused by microglial signaling to astrocytes. Figure 30A shows that syngeneic APPSWE+ / + neurons expressed telencephalic marker FOXG1. Figure 30B shows cortical layer markers CTIP2 and TBR1. Figure 30C shows the total amount of amyloid secreted by D50 syngeneic APPSWE+ / + neurons and WT controls. n=2, Student's t-test. Figure 30D shows syngeneic APPSWE+ / + avian cultures containing d80 neurons (MAP2+), wild-type hPSC-derived microglia (IBA1+) and astrocytes (GFAP+). Figure 30E shows that APPSWE+ / + avian cultures secreted more C3 than syngeneic control avian cultures. n=3, ANOVA with Sidak's post-hoc test. FIG. 30F provides that C3KOA avian cultures containing APPSWE+ / + neurons exhibited lower C3 secretion compared to APPSWE+ / + avian cultures containing wild-type astrocytes. C3KOM APPSWE+ / + avian cultures had lower secreted C3 levels. n=3 per group, ANOVA with Sidak's post-hoc test. FIG. 30G shows that APPSWE+ / + cultures containing microglia expressed higher levels of C1QA deposition compared to syngeneic control cultures. FIG. 30H shows a neuroinflammatory loop in an in vitro model of AD, where APPSWE+ / + neurons activated microglia, which in turn activated astrocytes, causing increased C3 release. [Figure 30-2] Same as above.
[0038] [Diagram 31]Figures 31A-31C show the generation of hematopoietic identity cells. Figure 31A shows that addition of erythropoietin (EPO) from day 6 allows the generation of CD235A+ red blood cells on day 10 of differentiation. Figure 31B shows that round hematopoietic cells progressively proliferate in semi-suspension by day 10. Figure 31C shows that VE-cadherin+ hemogenic endothelial cells were present in the differentiation cultures.
[0039] [Diagram 32] Figures 32A-32B show the generation of GFP+ hematopoietic cells from GPI-H2B-GFP hPSC lines. Figure 32A shows that upon PCR of the locus, the targeted line containing GFP produced a 1 kb product after H2B. Figure 32B shows that the GPI-H2B-GFP hPSC line at the pluripotent stage expressed GFP in all cells.
[0040] [Diagram 33] Figures 33A-33C show representative bright field and immunofluorescence images of microglial cells. Figure 33A shows that by day 11 of culture in IL-34 and M-CSF under serum or serum-free conditions, all differentiated cells were attached and cells displayed elongated morphology. Figure 33B shows that all cells expressed the myeloid transcription factor PU.1. Figure 33C shows that microglial cells upregulated IBA1 when co-cultured and developed into a branched morphology.
[0041] [Figure 34-1] Figures 34A-34B show the results of single-cell RNA sequencing of co-cultured hPSC-derived microglial cells. Figure 34A shows that the pairwise distances between cells in the microglial samples fell into a homogeneous unimodal distribution. Figure 34B shows that the pairwise distances between cells in the heterogeneous day 10 samples had multiple peaks. [Figure 34-2] Same as above.
[0042] [Diagram 35]Figures 35A-35B show phagocytosis of cells when challenged with yeast-antigen zymosan. Figure 35A shows microglial cells displaying zymosan-conjugated fluorescent beads as inclusions within 4 hours. Figure 35B shows astrocyte controls did not display fluorescent bead inclusions.
[0043] [Diagram 36] Figures 36A-36B show pre-synaptic and postsynaptic gene expression in hPSC-derived cortical neurons. Figure 36A shows hPSC-derived cortical neurons at D70, showing the punctate distribution of pre-synaptic SYNI and postsynaptic HOMER1, as well as putative synapses when both are juxtaposed (white arrows). Figure 36B shows that hPSC-derived cortical neurons at D70 expressed the postsynaptic marker PSD95 in a punctate distribution.
[0044] [Figure 37-1] Figures 37A-37C show C3 secretion in avian cultures under different conditions. Figure 37A shows that avian cultures with increased numbers of seeded astrocytes (50K) had fewer microglial cells (IBA1+) at day 7 (5x). Figure 37B shows that secretion of C3 in avian cultures NB / BAGC and NB:N2 basal media formulations was the lowest among all tested cell cultures. Figure 37C shows that hPSC-derived neurons killed by incubation in 70% methanol for 30 min showed bright CC3+, whereas viable cells showed no. [Figure 37-2] Same as above. [Figure 37-3] Same as above.
[0045] [Figure 38]Figures 38A-38C show quantification of IBA+ cells by immunofluorescence using a high content imaging microscope. Figure 38A shows that using an ImageExpress microscope of 9 fields of wells, cell scoring of %IBA1+ / DAPI in microglia / neuron (M / N) cultures was higher compared to tri-cultures at day 7. Figure 38B shows a representative image of the quantification of 9 fields of wells for cell scoring showing DAPI and IBA1 staining. Figure 38C shows cell scoring showing equal numbers of IBA1+ microglia and GFAP+ astrocytes between the different tri-cultures (TRI, C3KOM, C3KOA). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0046] The present disclosure relates to methods for generating microglial cells derived from stem cells (e.g., human stem cells), microglial cells obtained from such methods as well as compositions comprising same, and uses of such microglial cells for disease modeling and treating microglia-associated disorders.
[0047] The present disclosure provides an in vitro method for inducing stem cell differentiation.In certain embodiments, the method includes: a) contacting stem cell with at least one activator of Wingless (Wnt) signaling for up to about 24 hours; b) contacting cell with at least one inhibitor of Wnt signaling and at least one hematopoietic promoting cytokine to obtain a population of differentiated cells, wherein the differentiated cells are selected from the group consisting of cells expressing at least one erythro-myeloid progenitor (EMP) marker, cells expressing at least one pre-macrophage marker, and combinations thereof; and c) inducing the differentiation of the differentiated cells into cells expressing at least one microglia marker.
[0048] In certain embodiments, c) inducing differentiation of the differentiated cell into a cell expressing at least one microglial marker comprises culturing the differentiated cell with neurons for at least about 5 days. In certain embodiments, c) inducing differentiation of the differentiated cell into a cell expressing at least one microglial marker comprises culturing the differentiated cell with neurons for 4 days. In certain embodiments, c) inducing differentiation of the differentiated cell into a cell expressing at least one microglial marker comprises contacting the differentiated cell with at least one macrophage-promoting cytokine for at least about 5 days; and culturing the cell with neurons for at least about 5 days. In certain embodiments, the method comprises culturing the cell with neurons for at least 4 days.
[0049] In certain embodiments, the cells are contacted with at least one activator of Wnt signaling for about 20 hours. In certain embodiments, the cells are contacted with at least one activator of Wnt signaling for about 18 hours.
[0050] In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling for at least about 1 day up to about 5 days. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling for at least about 1 day up to 4 days. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling for at least about 2 days.
[0051] In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine for at least about 1 day and up to about 10 days. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine for at least 3 days and up to 11 days. In certain embodiments, the cells are contacted with at least one macrophage promoting cytokine for 7 days, 8 days, 9 days, 10 days, or 11 days. In certain embodiments, the cells are cultured with neurons for about 5 days. In certain embodiments, the cells are cultured with neurons for 4 days or 5 days.
[0052] In certain embodiments, contacting the stem cells with at least one activator of Wnt signaling generates cells expressing at least one mesodermal progenitor marker. In certain embodiments, the at least one mesodermal progenitor marker is selected from the group consisting of brachyury, KDR, and combinations thereof. In certain embodiments, contacting the cells with at least one inhibitor of Wnt signaling generates cells expressing at least one primary hematopoietic progenitor marker. In certain embodiments, the at least one primary hematopoietic progenitor marker is selected from the group consisting of KDR, CD235A, and combinations thereof. In certain embodiments, contacting the cells with at least one hematopoietic promoting cytokine further generates cells expressing at least one erythromyeloid progenitor (EMP) marker. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine for at least about 1 day to up to about 5 days and / or up to about 10 days to generate cells expressing at least one EMP marker. In certain embodiments, the at least one EMP marker is selected from the group consisting of Kit, CD41, CD235A, CD43, and combinations thereof. In certain embodiments, the cells expressing at least one EMP marker do not express CD45. In certain embodiments, the at least one pre-macrophage marker is selected from the group consisting of CD45, CSF1R, and combinations thereof. In certain embodiments, the cells expressing at least one pre-macrophage marker do not express Kit. In certain embodiments, the at least one microglial marker is selected from the group consisting of CX3CR1, PU.1, CD45, IBA1, P2RY12, TMEM119, SALL1, GPR34, C1QA, CD68, CD45, and combinations thereof. In certain embodiments, the at least one macrophage marker is selected from the group consisting of CD11B, Dectin, CD14, PU.1, CX3CR1, CD45, and combinations thereof.
[0053] In certain embodiments, at least one activator of Wnt signaling reduces glycogen synthase kinase 3β (GSK3β) for activation of Wnt signaling.In certain embodiments, at least one activator of Wnt signaling is selected from the group consisting of CHIR99021, Wnt-1, WNT3A, Wnt4, Wnt5a, WAY-316606, IQ1, QS11, SB-216763, BIO (6-bromoindirubin-3'-oxime), LY2090314, DCA, 2-amino-4-[3,4-(methylenedioxy)benzyl-amino]-6-(3-methoxyphenyl)pyrimidine, (hetero)arylpyrimidine, derivatives thereof, and combinations thereof.In certain embodiments, at least one activator of Wnt signaling is CHIR99021.
[0054] In certain embodiments, the at least one inhibitor of Wnt signaling is selected from the group consisting of XAV939, IWP2, DKK1, IWR1, peptides (Nile et al. Nat Chem Biol. 2018 Jun;14(6):582-590), porccupine inhibitor, LGK974, C59, ETC-159, Ant1.4Br / Ant1.4Cl, niclosamide, apicularen, bafilomycin, G007-LK, G244-LM, pyrvinium, NSC668036, 2,4-diamino-quinazoline, quercetin, ICG-001, PKF115-584, BC2059, Shizokaol D, derivatives thereof, and combinations thereof. In certain embodiments, the at least one inhibitor of Wnt signaling is IWP2.
[0055] In certain embodiments, at least one hematopoietic promoting cytokine is selected from the group consisting of VEGF, FGF, SCF, interleukin, TPO, and combinations thereof. In certain embodiments, the interleukin is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, and combinations thereof. In certain embodiments, the interleukin is selected from the group consisting of IL-6, IL-3, and combinations thereof. In certain embodiments, the FGF is selected from the group consisting of FGF1, FGF2, FGF3, FGF4, FGF7, FGF8, FGF10, FGF18, and combinations thereof. In certain embodiments, the FGF is FGF2.
[0056] In certain embodiments, the at least one macrophage-promoting cytokine is selected from the group consisting of M-CSF, IL-34, and combinations thereof.
[0057] In certain embodiments, the cells are contacted with at least one activator of Wnt signaling at a concentration between about 1 μM and about 6 μM. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling at a concentration between about 1 μM and about 10 μM. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration between about 1 ng / ml and about 50 ng / ml. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration between about 1 ng / ml and about 400 ng / ml. In certain embodiments, the cells are contacted with at least one macrophage promoting cytokine at a concentration between about 1 ng / ml and about 200 ng / ml.
[0058] In another aspect, the present disclosure provides a cell population of in vitro differentiated cells expressing at least one microglial marker, said in vitro differentiated cells being derived from stem cells by the methods of differentiation disclosed herein. Also provided are compositions comprising such cell populations.
[0059] In another aspect, the present disclosure provides a kit for inducing differentiation of stem cells, the kit comprising: (a) at least one inhibitor of Wnt signaling; (b) at least one activator of Wnt signaling; (c) at least one hematopoietic promoting cytokine; and (d) a neuron. In certain embodiments, the kit further comprises (e) at least one macrophage promoting cytokine.
[0060] In certain embodiments, the kit further comprises instructions for inducing differentiation of the stem cells into cells expressing at least one microglial marker.
[0061] In another aspect, the disclosure provides a composition comprising a population of in vitro differentiated cells, wherein at least about 50% of the cells in the population express at least one microglial marker, and less than about 25% of the cells in the population express at least one marker selected from the group consisting of stem cell markers, mesoderm progenitor markers, primary hematopoietic progenitor markers, EMP markers, premacrophage markers, and macrophage markers.
[0062] In another aspect, the present disclosure provides a method for preventing and / or treating neurodegenerative disease in a subject.In certain embodiments, the method comprises administering to the subject one of the following: (a) the population of differentiated microglial cells disclosed herein; (b) the composition disclosed herein; and (c) the composition disclosed herein.In certain embodiments, the method comprises administering to the subject colony-stimulating factor (CSF).
[0063] In certain embodiments, the neurodegenerative disease is Alzheimer's disease or amyotrophic lateral sclerosis (ALS). In certain embodiments, the neurodegenerative disease is Alzheimer's disease.
[0064] In certain embodiments, the CSF is selected from the group consisting of colony stimulating factor (GM-CSF) and M-CSF. In certain embodiments, the CSF is GM-CSF.
[0065] In another aspect, the present disclosure provides a CSF for use in the prevention and / or treatment of a neurodegenerative disease.
[0066] In another aspect, the disclosure provides for the use of CSF for the manufacture of a medicament for preventing and / or treating a neurodegenerative disease.
[0067] In another aspect, the disclosure provides a method for screening therapeutic compounds for treating a neurodegenerative disease, comprising: (a) contacting a population of differentiated microglial cells according to claim 34 with a test compound, wherein the microglial cells are derived from stem cells obtained from a subject having a neurodegenerative disease; and (b) measuring functional activity of the microglial cells, wherein a change in the functional activity of the microglial cells indicates that the test compound is likely capable of treating the neurodegenerative disease.
[0068] In certain embodiments, the change is a decrease or an increase. In certain embodiments, the functional activity of microglial cells comprises the release of complement C3. In certain embodiments, a decrease in the complement C3 released from microglial cells indicates that the therapeutic compound is likely to be able to treat the neurodegenerative disease. In certain embodiments, the functional activity of microglial cells comprises amyloid-beta phagocytosis by microglial cells. In certain embodiments, the neurodegenerative disease is Alzheimer's disease.
[0069] In another aspect, the present disclosure provides a method for screening therapeutic compounds for treating neurodegenerative diseases, comprising: (a) contacting a test compound with a composition comprising differentiated microglial cells, a population of astrocytes, and a population of neurons as disclosed herein; and (b) measuring the neurotoxicity of neurons, wherein the decrease in the neurotoxicity of neurons after contacting with the test compound indicates that the test compound is likely to be able to treat neurodegenerative diseases.In certain embodiments, the neurodegenerative disease is ALS disease.In certain embodiments, microglial cells induce reactive astrocytes that induce neurotoxicity to neurons.
[0070] This disclosure provides a step-by-step developmental paradigm that recapitulates primary hematopoiesis in the yolk sac, isolates pre-macrophages (pMacs) prior to their maturation into macrophages, and cultures these cells in a neural niche in vitro to generate bona fide human microglial cells in as little as 16 days. For clarity of disclosure, and not by way of limitation, the detailed description will be divided into the following subsections: 5.1 Definition; 5.2 Methods for differentiating stem cells; 5.3 Compositions containing microglia; 5.4 Treatment methods; and 5.5 Kit 5.6 Methods for screening therapeutic compounds 5.1 Definition
[0071] The terms used herein generally have their ordinary meaning in the art, within the context of this invention and in the specific context in which each term is used. Certain terms are explained below or elsewhere in this specification to provide additional guidance to the practitioner in describing the compositions and methods of the invention and methods for making and using same.
[0072] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by a person skilled in the art, which will depend in part on how the value is measured or determined, i.e., on the limitations of the measurement system. For example, "about" may mean within 3 standard deviations or more than 3 standard deviations, according to the practice in the art. Alternatively, "about" may mean within a range of up to 20%, e.g., up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term may mean within an order of magnitude of a value, e.g., within 5-fold, or within 2-fold.
[0073] As used herein, the term "signal transduction" in relation to "signal transduction proteins" refers to proteins that are activated or otherwise affected by ligands or some other stimuli that bind to membrane receptor proteins. Examples of signal transduction proteins include, but are not limited to, fibroblast growth factors (FGFs), SMADs, Wingless (Wnt) complex proteins, including beta-catenin, NOTCH, transforming growth factor beta (TGFβ), activin, nodal and glycogen synthase kinase 3β (GSK3β) proteins. For many cell surface receptors or internal receptor proteins, the ligand-receptor interaction is not directly related to the cell's response. Ligand-activated receptors may first interact with other proteins inside the cell before the final physiological effect of the ligand on the cell's behavior occurs. Often, the behavior of several interacting chains of cellular proteins changes after the receptor is activated or inhibited. The entire series of cellular changes induced by receptor activation is referred to as a signal transduction mechanism or signal transduction pathway.
[0074] As used herein, the term "signals" refers to internal and external factors that control changes in cell structure and function. These can be chemical or physical in nature.
[0075] As used herein, the term "ligand" refers to molecules and proteins that bind to receptors, such as TFGβ, activin, nodal, bone morphogenetic proteins (BMPs), and the like.
[0076] As used herein, "inhibitor" refers to a compound or molecule (e.g., small molecule, peptide, peptidomimetic, natural compound, siRNA, antisense nucleic acid, aptamer, or antibody) that interferes with (e.g., reduces, decreases, suppresses, eliminates, or blocks) the signaling function of a molecule or pathway. An inhibitor may be any compound or molecule that changes any activity of a specified protein (signaling molecule, any molecule involved in a specified signaling molecule, a specified associated molecule, e.g., Wingless (Wnt)) (e.g., but not limited to, signaling molecules described herein) through directly contacting Wnt signaling, contacting Wnt mRNA, causing changes in Wnt conformation, reducing Wnt protein levels, or interfering with Wnt interaction with signaling partners (e.g., including those described herein) and affecting the expression of Wnt target genes (e.g., those described herein). Inhibitors also include molecules that indirectly control Wnt biological activity by blocking upstream signaling molecules (e.g., in the extracellular domain, examples of signaling molecules). Inhibitors are described in terms of competitive inhibition (binding to the active site in such a manner as to preclude or reduce binding of another known binding compound) and allosteric inhibition (binding to the protein in such a way that alters the conformation of the protein in such a manner as to interfere with binding of the compound to the active site of the protein) in addition to inhibition induced by binding to and affecting a molecule upstream from a designated signaling molecule, resulting in inhibition of the designated molecule. Inhibitors may also be "direct inhibitors" that inhibit a signaling target or a signaling target pathway by actually contacting the signaling target.
[0077] As used herein, "activator" refers to a compound that increases, induces, stimulates, activates, promotes, or enhances the activation signaling function of a molecule or pathway, e.g., Wnt signaling, or FGF signaling.
[0078] As used herein, the term "derivative" refers to a chemical compound that has a similar core structure.
[0079] As used herein, the term "cell population" or "cell population" refers to a group of at least two cells. In non-limiting examples, a cell population may comprise at least about 10, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000 cells. A population may be a pure population that comprises one cell type. Alternatively, a population may comprise more than one cell type, for example, a mixed cell population.
[0080] As used herein, the term "stem cell" refers to a cell that has the ability to divide indefinitely in culture and give rise to specialized cells. Human stem cells refer to stem cells from humans.
[0081] As used herein, the term "embryonic stem cells" refers to primitive (undifferentiated) cells derived from preimplantation stage embryos, which can divide in culture for extended periods without differentiation and are known to develop into cells and tissues of the three major germ layers. Human embryonic stem cells refer to embryonic stem cells from humans. As used herein, the term "human embryonic stem cells" or "hESCs" refers to a type of pluripotent stem cell ("PSC") derived from early stage human embryos up to the blastocyst stage, which can divide in culture for extended periods without differentiation and are known to develop into cells and tissues of the three major germ layers.
[0082] As used herein, the term "embryonic stem cell line" refers to a population of embryonic stem cells cultured under in vitro conditions that allow proliferation without differentiation for up to several days, months or years.
[0083] As used herein, the term "totipotency" refers to the ability to give rise to every cell type of the body, as well as all of the cell types that populate extraembryonic tissues, such as the placenta.
[0084] As used herein, the term "pluripotency" refers to the ability to develop into more than one cell type of the body.
[0085] As used herein, the term "pluripotency" refers to the capacity to develop into an organism's three developmental germ layers, including endoderm, mesoderm, and ectoderm.
[0086] As used herein, the term "induced pluripotent stem cells" or "iPSCs" refers to a type of pluripotent stem cell similar to an embryonic stem cell, and which is formed by introducing certain embryonic genes (e.g., OCT4, SOX2, and KLF4 transgenes) (see, e.g., Takahashi and Yamanaka Cell 126, 663-676 (2006), which is incorporated herein by reference) into somatic cells, such as CI4, C72, etc.
[0087] As used herein, the term "somatic cell" refers to any cell in the body other than a gamete (egg or sperm); sometimes referred to as an "adult" cell.
[0088] As used herein, the term "somatic (adult) stem cells" refers to relatively rare undifferentiated cells found in many organs and differentiated tissues that have limited capacity for both self-renewal (in the laboratory) and differentiation. Such cells vary in their differentiation potential but are usually restricted to cell types in the organ of origin.
[0089] As used herein, the term "neuron" refers to a nerve cell, which is the primary functional unit of the nervous system. A neuron consists of a cell body and its processes--an axon and at least one dendrite. Neurons transmit information to other neurons or cells by releasing neurotransmitters at synapses.
[0090] As used herein, the term "proliferation" refers to an increase in cell number.
[0091] As used herein, the term "undifferentiated" refers to cells that have not yet developed into a specialized cell type.
[0092] As used herein, the term "differentiation" refers to the process by which unspecialized embryonic cells acquire the characteristics of specialized cells, such as heart, liver, or muscle cells. Differentiation is usually controlled by the interaction of the cell's genes with the physical and chemical conditions outside the cell, via signaling pathways involving proteins embedded in the cell surface.
[0093] As used herein, the term "directed differentiation" refers to the manipulation of stem cell culture conditions to induce differentiation into a particular (eg, desired) cell type, such as EMPs.
[0094] As used herein, the term "directed differentiation" in relation to stem cells refers to the use of small molecules, growth factor proteins, and other growth conditions to promote the transition of stem cells from a pluripotent state to a more mature or specialized cell fate (e.g., pMacs, macrophages, microglia, etc.).
[0095] As used herein, the term "induction of differentiation" in relation to a cell refers to changing an initial state cell type (genotype and / or phenotype) to a non-initial state cell type (genotype and / or phenotype). Thus, "induction of differentiation in stem cells" refers to inducing stem cells (e.g., human stem cells) to divide into progeny cells that have characteristics, e.g., genotype (e.g., changes in gene expression as determined by genetic analysis, e.g., microarrays) and / or phenotype (e.g., changes in expression of proteins, e.g., microglial markers), that differ from the stem cell.
[0096] As used herein, the term "cell culture" refers to the growth of cells in vitro in an artificial medium for research or medical treatment.
[0097] As used herein, the term "culture medium" refers to a liquid containing nutrients to cover, nourish and support cells in a culture vessel, e.g., a petri dish, a multi-well plate, etc. Culture medium may also contain growth factors that are added to produce desired changes in the cells.
[0098] As used herein, the term "contacting" a cell with a compound (e.g., at least one inhibitor, activator, and / or inducer) refers to placing the compound in a position that would allow it to touch the cells. Contacting may be accomplished using any suitable method. For example, contacting can be accomplished by adding the compound to a tube of cells. Contacting can also be accomplished by adding the compound to a culture medium containing the cells. Each compound (e.g., the inhibitors, activators, and inducers disclosed herein) can be added to the culture medium containing the cells while still in solution (e.g., a concentrated solution). Alternatively or additionally, the compound (e.g., the inhibitors, activators, and inducers disclosed herein) and the cells may be present in a formulated cell culture medium.
[0099] As used herein, the term "in vitro" refers to an artificial environment and to processes or reactions that occur within an artificial environment. Examples of in vitro environments include, but are not limited to, test tubes and cell cultures.
[0100] As used herein, the term "in vivo" refers to the natural environment (e.g., an animal or a cell) and to processes or reactions that occur within a natural environment, such as embryonic development, cell differentiation, neurulation, and the like.
[0101] As used herein, the term "expressing" with respect to a gene or protein refers to making mRNA or protein that can be observed using an assay, such as a microarray assay, an antibody staining assay, or the like.
[0102] As used herein, the term "marker" or "cell marker" refers to a gene or protein that identifies a particular cell or cell type. A marker for a cell may not be limited to one marker, but may refer to a "pattern" of markers such that a specified group of markers can identify a cell or cell type from another cell or cell type.
[0103] As used herein, when referring to any cell disclosed herein, the terms "derived from" or "established from" or "differentiated from" refer to cells obtained (e.g., isolated, purified, etc.) from parent cells in a cell line, tissue (e.g., dissociated embryos) or body fluid using any manipulation, such as, but not limited to, isolation of single cells, culture in vitro, treatment and / or mutagenesis, e.g., with proteins, chemicals, radiation, infection with viruses, transfection of DNA sequences with morphogens, etc., selection (e.g., by continuous culture) of any cells contained in the cultured parent cells. Derived cells may be selected from a mixed population by response to growth factors, cytokines, a selected course of cytokine treatment, adhesion, lack of adhesion, sorting procedures, etc.
[0104] As used herein, an "individual" or "subject" is a vertebrate, such as a human or a non-human animal, such as a mammal. Mammals include, but are not limited to, humans, primates, livestock, sports animals, rodents and pets. Non-limiting examples of non-human animal subjects include rodents, such as mice, rats, hamsters and guinea pigs; rabbits; dogs; cats; sheep; pigs; goats; cows; horses; and non-human primates, such as apes and monkeys.
[0105] As used herein, the term "disease" refers to any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.
[0106] As used herein, the term "treating" or "treatment" refers to clinical intervention in an attempt to change the progression of disease in the individual or cell being treated, and may be performed for prevention or during the progression of clinical disease. The therapeutic effects of treatment include, but are not limited to, preventing the appearance or recurrence of disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and remission or improving prognosis. By preventing the progression of a disease or disorder, treatment can not only prevent the deterioration caused by the disorder in a subject who has been affected or diagnosed or is suspected of having the disorder, but may also prevent the onset of the disorder or symptoms of the disorder in a subject who is at risk of the disorder or is suspected of having the disorder. 5.2. Methods for Differentiating Stem Cells
[0107] The present disclosure provides an in vitro method for inducing differentiation of stem cells (e.g., human stem cells). Non-limiting examples of human stem cells include human embryonic stem cells (hESCs), human pluripotent stem cells (hPSCs), human induced pluripotent stem cells (hiPSCs), human parthenogenetic stem cells, primordial germ cell-like pluripotent stem cells, epiblast stem cells, F-class pluripotent stem cells, somatic stem cells, cancer stem cells, or any other cells capable of lineage-specific differentiation. In certain embodiments, the human stem cells are human embryonic stem cells (hESCs). In certain embodiments, the human stem cells are human induced pluripotent stem cells (hiPSCs).
[0108] The present disclosure is directed to stem cell-derived microglial cells. In certain embodiments, differentiation of stem cells into microglial cells includes in vitro differentiation of stem cells into cells expressing at least one mesodermal progenitor marker, in vitro differentiation of stem cells into cells expressing at least one primary hematopoietic progenitor marker, in vitro differentiation of stem cells into cells expressing at least one erythro-myeloid progenitor (EMP) marker, in vitro differentiation of cells expressing at least one pre-macrophage (also known as macrophage precursor) (pMac) marker, and in vitro differentiation of cells expressing at least one pMac marker into cells expressing at least one microglial marker. In certain embodiments, differentiation of stem cells into microglial cells further includes in vitro differentiation of cells expressing at least one pMac marker into cells expressing at least one macrophage marker, and in vitro differentiation of cells expressing at least one macrophage marker into cells expressing at least one microglial marker.
[0109] In certain embodiments, the present disclosure provides a method for inducing differentiation of stem cells, comprising: a) contacting stem cells with at least one activator of Wingless (Wnt) signaling; b) contacting the cells with at least one inhibitor of Wnt signaling and at least one hematopoietic promoting cytokine to obtain a population of differentiated cells selected from the group consisting of cells expressing at least one erythro-myeloid progenitor (EMP) marker, cells expressing at least one pre-macrophage marker, and combinations thereof; and c) inducing differentiation of the differentiated cells into cells expressing at least one microglia marker. In certain embodiments, inducing differentiation of the differentiated cells into cells expressing at least one microglia marker comprises culturing the differentiated cells with neurons. In certain embodiments, inducing differentiation of the differentiated cells into cells expressing at least one microglia marker comprises contacting the differentiated cells with at least one macrophage promoting cytokine; and culturing the cells with neurons. 5.2.1. Differentiation of stem cells into mesodermal precursors
[0110] In certain embodiments, cells expressing at least one mesodermal progenitor marker are differentiated in vitro from stem cells by contacting the stem cells (e.g., human stem cells) with at least one activator of Wnt signaling (e.g., CHIR99021) (referred to as "Wnt activator"). In certain embodiments, the stem cells are further contacted with at least one BMP activator, such as a BMP molecule (e.g., BMP4) and at least one activin protein (e.g., activin A).
[0111] Non-limiting examples of mesodermal progenitor markers include brachyury, KDR, and combinations thereof.
[0112] As used herein, the term "Wnt" or "Wingless" in relation to a ligand refers to a group of secreted proteins that can interact with Wnt receptors, such as Frizzled and receptors in the LRPDerailed / RYK receptor family (i.e., Int1 (integration 1) in humans). As used herein, the term "Wnt" or "Wingless" in relation to a signaling pathway refers to a signaling pathway that is composed of a Wnt family ligand and a Wnt family receptor, such as Frizzled and LRPDerailed / RYK receptor, and is mediated with or without β-catenin. For purposes described herein, a preferred Wnt signaling pathway is mediated by β-catenin, such as WNT / -catenin.
[0113] In certain embodiments, at least one Wnt activator reduces glycogen synthase kinase 3β (GSK3β) for activation of Wnt signaling. Thus, the Wnt activator may be a GSK3β inhibitor. GSK3P inhibitors can activate WNT signaling pathway, see, for example, Cadigan, et al., J Cell Sci. 2006;119:395-402; Kikuchi, et al., Cell Signaling. 2007;19:659-671, which are incorporated herein by reference in their entirety. As used herein, the term "glycogen synthase kinase 3β inhibitor" refers to a compound that inhibits glycogen synthase kinase 3β enzyme, see, for example, Doble, et al., J Cell Sci. 2003;116:1175-1186, which are incorporated herein by reference in their entirety.
[0114] Non-limiting examples of Wnt activator or GSK3β inhibitor are disclosed in WO2011 / 149762, Chambers (2012), and Calder et al., J Neurosci. 2015 Aug 19;35(33):11462-81, which are incorporated by reference in their entirety.In certain embodiments, at least one Wnt activator is a small molecule selected from the group consisting of CHIR99021, its derivative, and mixtures thereof.In certain embodiments, at least one Wnt activator is CHIR99021.
[0115] "CHIR99021" (also known as "aminopyrimidine" or "3-[3-(2-carboxyethyl)-4-methylpyrrole-2-methylidenyl]-2-indolinone") refers to the IUPAC name 6-(2-(4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-ylamino)ethylamino)nicotinonitrile, having the formula: [ka]
[0116] CHIR99021 is highly selective, exhibiting nearly 1000-fold selectivity against a panel of related and unrelated kinases, with IC50=6.7 nM against human GSK3β and nanomolar IC50 values against the rodent GSK3β homologue.
[0117] Non-limiting examples of Wnt activators include CHIR99021, Wnt-1, WNT3A, Wnt4, Wnt5a, WAY-316606, IQ1, QS11, SB-216763, BIO(6-bromoindirubin-3'-oxime), LY2090314, DCA, 2-amino-4-[3,4-(methylenedioxy)benzyl-amino]-6-(3-methoxyphenyl)pyrimidine, (hetero)arylpyrimidine, their derivatives, and their combinations.In certain embodiments, the Wnt activator is CHIR99021.
[0118] In certain embodiments, BMP active agent is BMP molecule.Non-limiting examples of BMP include BMP1, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, BMP8b, BMP10, BMP11, BMP15, their derivatives and their mixtures.In certain embodiments, BMP active agent is BMP4.
[0119] Non-limiting examples of activin proteins include activin A, activin AB, activin C, activin B, and activin AC, derivatives thereof, and combinations thereof. In certain embodiments, the activin protein is activin A.
[0120] To differentiate the stem cells in vitro into cells expressing at least one mesodermal progenitor marker, the stem cells may be contacted with at least one activator of Wnt signaling for up to about 10 hours, up to about 15 hours, up to about 20 hours, or up to about 25 hours. In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling for up to about 20 hours. In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling for at least about 10 hours, at least about 15 hours, at least about 20 hours, or at least about 25 hours. In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling for between about 10 hours and about 25 hours, between about 10 hours and about 15 hours, between about 10 hours and about 20 hours, between about 15 hours and about 25 hours, or between about 15 hours and about 20 hours. In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling for between about 10 hours and about 20 hours. In certain embodiments, the stem cell is contacted with at least one activator of Wnt signaling for about 15 hours to about 20 hours. In certain embodiments, the stem cell is contacted with at least one activator of Wnt signaling for about 10 hours, about 15 hours, or about 20 hours, or about 25 hours. In certain embodiments, the stem cell is contacted with at least one activator of Wnt signaling for about 15 hours or about 20 hours. In certain embodiments, the stem cell is contacted with at least one activator of Wnt signaling for 16 hours, 17 hours, 18 hours, 19 hours, or 20 hours. In certain embodiments, the stem cell is contacted with at least one activator of Wnt signaling for 18 hours.
[0121] In certain embodiments, the stem cell may be further contacted with at least one BMP activator (e.g., BMP4) to differentiate the stem cell into a cell expressing at least one mesodermal progenitor marker in vitro. In certain embodiments, the stem cell is further contacted with at least one activin protein (e.g., activin A). In certain embodiments, the stem cell is contacted simultaneously or concomitantly with a Wnt activator, a BMP activator and an activin protein. In certain embodiments, the stem cell is contacted simultaneously with at least one Wnt activator, at least one BMP activator and at least one activin protein for up to about 10 hours, up to about 15 hours, up to about 20 hours, or up to about 25 hours. In certain embodiments, the stem cell is contacted simultaneously with at least one activator of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) for at least about 10 hours, at least about 15 hours, at least about 20 hours, or at least about 25 hours. In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) simultaneously for about 10 hours to about 25 hours, about 10 hours to about 15 hours, about 10 hours to about 20 hours, about 15 hours to about 25 hours, or about 15 hours to about 20 hours. In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) simultaneously for about 15 hours to about 20 hours. In certain embodiments, the stem cells are contacted with at least one Wnt activator, at least one BMP activator, and at least one activin protein simultaneously for about 15 hours or about 20 hours.In certain embodiments, the stem cells are contacted with at least one Wnt activator, at least one BMP activator, and at least one activin protein for 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 hours simultaneously. In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) for about 20 hours simultaneously. In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) for 18 hours simultaneously.
[0122] In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling at a concentration of about 1 μM to about 100 μM, about 1 μM to about 20 μM, about 1 μM to about 15 μM, about 1 μM to about 10 μM, about 1 μM to about 6 μM, about 6 μM to about 10 μM, about 6 μM to about 15 μM, about 15 μM to about 20 μM, about 20 μM to about 30 μM, about 30 μM to about 40 μM, about 40 μM to about 50 μM, about 50 μM to about 60 μM, about 60 μM to about 70 μM, about 70 μM to about 80 μM, about 80 μM to about 90 μM, or about 90 μM to about 100 μM. In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling at a concentration of about 1 μM to about 6 μM. In certain embodiments, the stem cells are contacted with at least one activator of Wnt signaling at a concentration of about 3 μM.
[0123] In certain embodiments, the stem cells are administered in a culture medium containing at least one BMP activator and about 1 ng / ml to about 100 ng / ml, about 1 ng / ml to about 20 ng / ml, about 1 ng / ml to about 15 ng / ml, about 1 ng / ml to about 10 ng / ml, about 1 ng / ml to about 5 ng / ml, about 5 ng / ml to about 10 ng / ml, about 5 ng / ml to about 15 ng / ml, about 15 ng / ml to about 25 ng / ml, about 15 The stem cell is contacted with a concentration of about ng / ml to about 20ng / ml, about 20ng / ml to about 30ng / ml, about 30ng / ml to about 40ng / ml, about 40ng / ml to about 50ng / ml, about 50ng / ml to about 60ng / ml, about 60ng / ml to about 70ng / ml, about 70ng / ml to about 80ng / ml, about 80ng / ml to about 90ng / ml, or about 90ng / ml to about 100ng / ml.In certain embodiments, the stem cell is contacted with at least one BMP activator at a concentration between about 20ng / ml and about 40ng / ml.In certain embodiments, the stem cell is contacted with at least one BMP activator at a concentration of about 30ng / ml.
[0124] In certain embodiments, the stem cells are administered at least one activin protein and at least about 1 ng / ml to about 100 ng / ml, about 1 ng / ml to about 20 ng / ml, about 1 ng / ml to about 15 ng / ml, about 1 ng / ml to about 10 ng / ml, about 1 ng / ml to about 5 ng / ml, about 5 ng / ml to about 10 ng / ml, about 5 ng / ml to about 15 ng / ml, about 15 ng / ml to about 25 ng / ml, about The stem cell is contacted with a concentration of about 15ng / ml to about 20ng / ml, about 20ng / ml to about 30ng / ml, about 30ng / ml to about 40ng / ml, about 40ng / ml to about 50ng / ml, about 50ng / ml to about 60ng / ml, about 60ng / ml to about 70ng / ml, about 70ng / ml to about 80ng / ml, about 80ng / ml to about 90ng / ml, or about 90ng / ml to about 100ng / ml.In certain embodiments, the stem cell is contacted with at least one activin protein at a concentration between about 5ng / ml to about 10ng / ml.In certain embodiments, the stem cell is contacted with at least one activin protein at a concentration of about 7.5ng / ml. 5.2.2. Differentiation of Mesodermal Precursors to Primary Hematopoietic Progenitors
[0125] In certain embodiments, the cells expressing at least one primary hematopoietic progenitor marker are differentiated in vitro from the cells expressing at least one mesodermal progenitor marker by contacting the cells expressing at least one mesodermal progenitor marker with at least one inhibitor of Wnt signaling (referred to as "Wnt inhibitor") (e.g., IWP2). In certain embodiments, the stem cells are further contacted with at least one BMP activator (e.g., BMP molecule, e.g., BMP4) and at least one activin protein (e.g., activin A). Non-limiting examples of primary hematopoietic progenitor markers include KDR, CD235A, and combinations thereof.
[0126] The term "Wnt signaling inhibitor" or "Wnt inhibitor" as used herein refers to any agent that inhibits Wnt signaling pathway and thus reproduces the function of Wnt, not just any agent that can act by directly inhibiting the normal function of Wnt protein.Examples of Wnt inhibitors include XAV939 (Huang et al. Nature 461:614-620 (2009)), vitamin A (retinoic acid), lithium, flavonoids, Dickkopf1 (Dkk1), insulin-like growth factor binding protein (IGFBP) (WO2009 / 131166), and siRNA against β-catenin.
[0127] Non-limiting examples of Wnt inhibitors include XAV939, IWR compounds, IWP compounds (e.g., IWP-2), DKK1 (Dickkopf protein 1), IWR1, peptides (Nile et al. peptides (Nile et al Nat Chem Biol. 2018 Jun;14(6):582-590)), porcupine inhibitors, LGK974, C59, ETC-159, Ant1.4Br / Ant1.4Cl, niclosamide, apicularen, bafilomycin, G007-LK, G244-LM, pyrvinium, NSC668036, 2,4-diamino-quinazoline, quercetin, ICG-001, PKF115-584, BC2059, Shizokaol D, derivatives thereof, and combinations thereof. In certain embodiments, the Wnt inhibitor is IWP2.
[0128] Wnt inhibitors may be those described in WO09155001 and Chen et al., Nat Chem Biol 5:100-7 (2009), which are incorporated by reference in their entireties.
[0129] XAV939 is a potent small molecule inhibitor of tankyrase (TNKS) 1 and 2, with IC of 11 and 4 nM. 50Each has a different value. Huang et al., Nature 461:614-620 (2009). By inhibiting TNKS activity, XAV939 increases the protein level of the Axin-GSK3β complex and promotes the degradation of β-catenin in SW480 cells. Known Wnt inhibitors include Dickkopf proteins, secreted Frizzled-related proteins (sFRPs), Wnt inhibitory factor 1 (WIF-1), and Soggy. Members of the Dickkopf-related protein family (Dkk-1 to 4) are secreted proteins and have two cysteine-rich domains, separated by a linker region. Dkk-3 and -4 also have one prokineticin domain. Dkk-1, -2, -3, and -4 function as antagonists of canonical Wnt signaling by binding to LRP5 / 6, preventing the interaction of LRP5 / 6 with the Wnt-Frizzled complex. Dkk-1, -2, -3, and -4 also bind cell surface Kremen-1 or -2 and promote LRP5 / 6 internalization. No antagonistic activity of Dkk-3 has been demonstrated. Dkk proteins have distinct expression patterns in adult and embryonic tissues and have widespread effects on tissue development and morphogenesis.
[0130] The Dkk family also includes Soggy, which is homologous to Dkk-3 but not to other family members. sFRPs are a family of five Wnt-binding glycoproteins that are similar to membrane-bound Frizzled. These, the largest family of Wnt inhibitors, contain two groups, the first consisting of sFRP1, 2, and 5, and the second including sFRP3 and 4. All are secreted, are derived from unique genes, and all are not alternative splice forms of the Frizzled family. Each sFRP contains an N-terminal cysteine-rich domain (CRO). Another Wnt inhibitor is WIF-1 (Wnt inhibitory factor 1), a secreted protein that binds to Wnt proteins and inhibits their activity. "IWP2" or "Inhibitor of WNT Production-2" refers to the IUPAC name N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide, which has the following formula: [ka]
[0131] IWP-2 inhibits the WNT pathway at the level of the pathway activator porcupine (IC 50 = 27 nM). Porcupine is a membrane-bound acyltransferase that palmitoylates WNT proteins, resulting in WNT secretion and signaling capacity.
[0132] In certain embodiments, to differentiate in vitro cells expressing at least one primary hematopoietic progenitor marker, cells expressing at least one mesodermal progenitor marker are contacted with at least one inhibitor of Wnt signaling for at least about 1 day, or at least about 2 days. In certain embodiments, cells are contacted with at least one inhibitor of Wnt signaling for at least about 2 days. In certain embodiments, cells are contacted with at least one inhibitor of Wnt signaling for up to about 1 day, up to about 2 days, up to about 3 days, or up to about 4 days. In certain embodiments, cells are contacted with at least one inhibitor of Wnt signaling for up to 4 days. In certain embodiments, cells are contacted with at least one inhibitor of Wnt signaling for about 1 day to about 5 days, about 1 day to about 4 days, about 1 day to about 3 days, or about 1 day to about 2 days. In certain embodiments, cells are contacted with at least one inhibitor of Wnt signaling for 2 days to about 5 days. In certain embodiments, cells are contacted with at least one inhibitor of Wnt signaling for 1 day to 3 days. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling for about 1 day, about 2 days, about 3 days, or about 4 days.In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling for 1 day, 2 days, 3 days, or 4 days.In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling for about 2 days.
[0133] In certain embodiments, the cells expressing at least one mesodermal precursor marker may be further contacted with at least one BMP activator (e.g., BMP4) to differentiate the cells expressing at least one mesodermal precursor marker into cells expressing at least one primary hematopoietic progenitor marker in vitro. In certain embodiments, the cells expressing at least one mesodermal precursor marker are further contacted with at least one activin protein (e.g., activin A). In certain embodiments, the cells expressing at least one mesodermal precursor marker are contacted simultaneously or concomitantly with a Wnt inhibitor, a BMP activator and an activin protein. In certain embodiments, the cells expressing at least one mesodermal precursor marker are contacted simultaneously with at least one inhibitor of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) for at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, or at least about 5 days. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) simultaneously for up to about 1 day, up to about 2 days, up to about 3 days, up to about 4 days, or up to about 5 days. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling for about 1 to about 5 days, for about 1 to about 4 days, for about 1 to about 3 days, or for about 1 to about 2 days. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) simultaneously for 1 to about 3 days. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) simultaneously for about 1 day, about 2 days, about 3 days, about 4 days, or about 5 days.In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) simultaneously for 1, 2, 3, 4, or 5 days. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling, at least one BMP activator (e.g., BMP4), and at least one activin protein (e.g., activin A) simultaneously for about 2 days.
[0134] In certain embodiments, cells expressing at least one mesodermal progenitor marker are contacted with at least one inhibitor of Wnt signaling at a concentration of about 1 μM to about 100 μM, about 1 μM to about 20 μM, about 1 μM to about 15 μM, about 1 μM to about 10 μM, about 1 μM to about 5 μM, about 5 μM to about 10 μM, about 5 μM to about 15 μM, about 15 μM to about 20 μM, about 20 μM to about 30 μM, about 30 μM to about 40 μM, about 40 μM to about 50 μM, about 50 μM to about 60 μM, about 60 μM to about 70 μM, about 70 μM to about 80 μM, about 80 μM to about 90 μM, or about 90 μM to about 100 μM. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling at a concentration of about 1 μM to about 10 μM. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling at a concentration of about 1 μM to about 5 μM. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling at a concentration of about 2 μM. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling at any one of the above concentrations every day, every other day, or every two days. In certain embodiments, the cells are contacted with at least one inhibitor of Wnt signaling at a concentration of about 2 μM every day.
[0135] In certain embodiments, cells expressing at least one mesodermal progenitor marker are treated with at least one BMP activator and a marker selected from the group consisting of about 1 ng / ml to about 100 ng / ml, about 1 ng / ml to about 20 ng / ml, about 1 ng / ml to about 15 ng / ml, about 1 ng / ml to about 10 ng / ml, about 1 ng / ml to about 5 ng / ml, about 5 ng / ml to about 10 ng / ml, about 5 ng / ml to about 15 ng / ml, about 15 ng / ml to about The cell is contacted at a concentration of 25ng / ml, about 15ng / ml to about 20ng / ml, about 20ng / ml to about 30ng / ml, about 30ng / ml to about 40ng / ml, about 40ng / ml to about 50ng / ml, about 50ng / ml to about 60ng / ml, about 60ng / ml to about 70ng / ml, about 70ng / ml to about 80ng / ml, about 80ng / ml to about 90ng / ml, or about 90ng / ml to about 100ng / ml. In certain embodiments, the stem cell is contacted with at least one BMP activator at a concentration between about 30ng / ml to about 50ng / ml. In certain embodiments, the cell is contacted with at least one BMP activator at a concentration of about 40ng / ml. In certain embodiments, the cell is contacted with at least one BMP activator at any one of the above concentrations every day, every other day, or every two days. In certain embodiments, the cells are contacted daily with at least one BMP activator at a concentration of about 40 ng / ml.
[0136] In certain embodiments, cells expressing at least one mesodermal progenitor marker are co-cultured with at least one activin protein and at least one activin protein in a concentration of from about 1 ng / ml to about 100 ng / ml, from about 1 ng / ml to about 20 ng / ml, from about 1 ng / ml to about 15 ng / ml, from about 1 ng / ml to about 10 ng / ml, from about 1 ng / ml to about 5 ng / ml, from about 5 ng / ml to about 10 ng / ml, from about 5 ng / ml to about 15 ng / ml, from about 15 ng / ml to about 15 ng / ml, The cells are contacted with at least one activin protein at a concentration of about 5ng / ml to about 15ng / ml. In certain embodiments, the cells are contacted with at least one activin protein at a concentration of about 10ng / ml. In certain embodiments, the cells are contacted with at least one activin protein at any one of the above concentrations every day, every other day, or every two days. In certain embodiments, the cells are contacted daily with at least one activin protein at a concentration of about 10 ng / ml. 5.2.3. Differentiation of Primary Hematopoietic Progenitors into EMP, pMac, and Combined Cell Populations
[0137] In certain embodiments, the cell population of differentiated cells is differentiated in vitro from cells expressing at least one primary hematopoietic progenitor marker by contacting the cells with at least one hematopoietic cytokine, and the differentiated cells are selected from the group consisting of cells expressing at least one erythro-myeloid progenitor (EMP) marker, cells expressing at least one pMac marker, and combinations thereof.In certain embodiments, the hematopoietic cytokine includes, but is not limited to, VEGF and FGF signaling activator.In certain embodiments, the hematopoietic cytokine includes VEGF and FGF2.
[0138] In certain embodiments, differentiation involves two stages: (1) differentiation of primary hematopoietic progenitors into erythromyeloid precursors (EMPs); and (2) differentiation of EMPs into pMacs. In certain embodiments, the molecules inducing both stages of differentiation are hematopoietic cytokines. For example, hematopoietic cytokines involved in the first stage include, but are not limited to, VEGF and FGF signaling activator. In certain embodiments, hematopoietic cytokines involved in the first stage include, but are not limited to, VEGF and FGF2. Hematopoietic cytokines involved in the second stage include, but are not limited to, stem cell factor (SCF), interleukin (IL), and thrombopoietin (TPO). In certain embodiments, hematopoietic cytokines involved in the second stage include, but are not limited to, SCF, IL-6, IL-3, and TPO.
[0139] KDR + CD235A cells and KDR + CD235A + Unsorted samples containing both populations of cells were sorted KDR + CD235A + It was found that the KDR population produced hematopoietic cells with nearly the same efficiency as the KDR population, due to its robust production of hematopoietic cells. + CD235A +This demonstrates that it is not necessary to purify cells. In certain embodiments, the cell population comprises cells that express at least one primary hematopoietic progenitor marker and is contacted with at least one hematopoietic promoting cytokine. In certain embodiments, the cell population comprises cells that do not express at least one primary hematopoietic progenitor marker. In certain embodiments, the cells that express at least one primary hematopoietic progenitor marker are not selected or isolated from the cell population before contacting the cell population with at least one hematopoietic promoting cytokine.
[0140] Non-limiting examples of EMP markers include Kit, CD41, CD235A, CD43, and combinations thereof. In certain embodiments, cells that express at least one EMP marker do not express CD45.
[0141] Non-limiting examples of pre-macrophage (pMac) markers include CD45, CSF1R, and combinations thereof.
[0142] Non-limiting examples of hematopoietic promoting cytokines include VEGF, FGF signaling activator, SCF, interleukins, TPO, and combinations thereof. Non-limiting examples of FGF signaling activators (referred to as "FGF activators") include FGF1, FGF2, FGF3, FGF4, FGF7, FGF8, FGF10, FGF18, derivatives thereof, and mixtures thereof. In certain embodiments, at least one FGF activator is FGF2. Non-limiting examples of interleukins include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, and IL-15. In certain embodiments, the interleukins are IL6, IL-3, derivatives thereof, and mixtures thereof. In certain embodiments, the at least one hematopoietic promoting cytokine is selected from the group consisting of VEGF, FGF2, SCF, IL-6, IL-3, TPO, or a combination thereof. In certain embodiments, the at least one hematopoietic promoting cytokine comprises VEGF and FGF2. In certain embodiments, the at least one hematopoietic promoting cytokine comprises SCF, IL-6, IL-3, and TPO.
[0143] To differentiate in vitro cells expressing at least one primary hematopoietic progenitor marker into cells expressing at least one EMP marker, cells expressing at least one primary hematopoietic progenitor marker are contacted with at least one hematopoietic promoting cytokine for at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, or at least about 5 days. In certain embodiments, cells are contacted with at least one hematopoietic promoting cytokine for at least about 1 day. In certain embodiments, cells are contacted with at least one hematopoietic promoting cytokine for up to about 1 day, up to about 2 days, up to about 3 days, up to about 4 days, or up to about 5 days, or up to about 10 days. In certain embodiments, cells are contacted with at least one hematopoietic promoting cytokine for up to about 10 days. In certain embodiments, cells are contacted with at least one hematopoietic promoting cytokine for between about 1 day and about 5 days, between about 1 day and about 10 days, or between about 5 days and about 10 days. In certain embodiments, cells are contacted with at least one hematopoietic promoting cytokine for between about 1 day and about 5 days. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine for 5 days to about 10 days. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine for about 1 day, about 2 days, about 3 days, about 4 days, or about 5 days, or about 10 days. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine for about 2 days or about 5 days, or about 10 days. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine for 2 days, 6 days, or 8 days. In certain embodiments, the at least one hematopoietic promoting cytokine comprises VEGF, FGF signaling activator, or a combination thereof. In certain embodiments, the at least one hematopoietic promoting cytokine comprises VEGF and FGF2.
[0144] To differentiate in vitro cells expressing at least one EMP marker into cells expressing at least one pMac marker, cells expressing at least one EMP marker are contacted with at least one hematopoietic promoting cytokine for up to about 2 days, up to about 3 days, up to about 4 days, up to about 5 days, or up to about 10 days. In certain embodiments, cells are contacted with at least one hematopoietic promoting cytokine for up to about 5 days. In certain embodiments, cells are contacted with at least one hematopoietic promoting cytokine for up to 6 days. In certain embodiments, cells are contacted with at least one hematopoietic promoting cytokine for at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, or at least about 6 days. In certain embodiments, cells are contacted with at least one hematopoietic promoting cytokine for at least about 2 days. In certain embodiments, the cells are contacted with the at least one hematopoietic promoting cytokine for about 2 to about 10 days, about 2 to about 5 days, or about 5 to about 10 days, about 2 to about 3 days, about 3 to about 6 days, or about 3 to about 5 days. In certain embodiments, the cells are contacted with the at least one hematopoietic promoting cytokine for about 2 to about 5 days, or about 5 to about 10 days. In certain embodiments, the cells are contacted with the at least one hematopoietic promoting cytokine for about 2 days, about 3 days, about 4 days, about 5 days, or about 6 days. In certain embodiments, the cells are contacted with the at least one hematopoietic promoting cytokine for about 5 days. In certain embodiments, the cells are contacted with the at least one hematopoietic promoting cytokine for 4 days or 6 days. In certain embodiments, the at least one hematopoietic promoting cytokine comprises SCF, interleukin, and TPO. In certain embodiments, the at least one hematopoietic promoting cytokine comprises SCF, IL-6, IL-3, and TPO.
[0145] In certain embodiments, the cells are administered in the presence of at least one hematopoietic promoting cytokine and a cytotoxic T cell line comprising at least about 1 ng / ml to about 400 ng / ml, about 100 ng / ml to about 400 ng / ml, about 200 ng / ml to about 400 ng / ml, about 300 ng / ml to about 400 ng / ml, about 100 ng / ml to about 300 ng / ml, about 100 ng / ml to about 200 ng / ml, about 1 ng / ml to about 00 ng / ml, about 1 ng / ml to about 20 ng / ml, about 1 ng / ml to about 15 ng / ml, about 1 ng / ml to about 10 ng / ml, about 1 ng / ml to about 5 ... The cells are contacted with at least one hematopoietic promoting cytokine at a concentration of about 1 ng / ml to about 10 ng / ml, about 5 ng / ml to about 15 ng / ml, about 15 ng / ml to about 25 ng / ml, about 15 ng / ml to about 20 ng / ml, about 20 ng / ml to about 30 ng / ml, about 30 ng / ml to about 40 ng / ml, about 40 ng / ml to about 50 ng / ml, about 50 ng / ml to about 60 ng / ml, about 60 ng / ml to about 70 ng / ml, about 70 ng / ml to about 80 ng / ml, about 80 ng / ml to about 90 ng / ml, or about 90 ng / ml to about 100 ng / ml. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration of between about 1 ng / ml to about 10 ng / ml. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration of about 5 ng / ml. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration between about 1 ng / ml and about 50 ng / ml. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration of about 5 ng / ml, about 10 ng / ml, about 15 ng / ml, about 20 ng / ml, about 30 ng / ml, or about 50 ng / ml. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration between about 50 ng / ml and about 150 ng / ml. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration of about 100 ng / ml. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration between about 150 ng / ml and about 250 ng / ml.In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration of about 200ng / ml. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at any one of the above concentrations every day, every other day, or every two days. In certain embodiments, the cells are contacted with at least one hematopoietic promoting cytokine at a concentration of about 5ng / ml, about 10ng / ml, about 15ng / ml, about 20ng / ml, about 30ng / ml, about 50ng / ml, about 100ng / ml, or about 200ng / ml every day.
[0146] In certain embodiments, the at least one hematopoietic promoting cytokine comprises VEGF, FGF2, or a combination thereof. In certain embodiments, the at least one hematopoietic promoting cytokine comprises SCF, IL3, IL-6, TPO, or a combination thereof. In certain embodiments, the concentration of VEGF is between about 5 ng / ml and about 50 ng / ml. In certain embodiments, the concentration of VEGF is about 15 ng / ml. In certain embodiments, the concentration of FGF2 is between about 1 ng / ml and about 50 ng / ml. In certain embodiments, the concentration of FGF2 is about 5 ng / ml. In certain embodiments, the concentration of SCF is between about 50 ng / ml and about 400 ng / ml. In certain embodiments, the concentration of SCF is about 100 ng / ml. In certain embodiments, the concentration of SCF is about 200 ng / ml. In certain embodiments, the concentration of IL-6 is between about 2 ng / ml and about 200 ng / ml. In certain embodiments, the concentration of IL-6 is about 10 ng / ml. In certain embodiments, the concentration of IL-6 is about 20ng / ml. In certain embodiments, the concentration of IL-3 is between about 1ng / ml and about 50ng / ml. In certain embodiments, the concentration of IL-3 is about 30ng / ml. In certain embodiments, the concentration of TPO is between about 3ng / ml and about 50ng / ml. In certain embodiments, the concentration of TPO is about 30ng / ml. 5.2.4. Differentiation of EMPs and / or pMacs into microglial cells
[0147] In certain embodiments, cells expressing at least one microglial marker are differentiated in vitro from differentiated cells (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) obtained according to the method described in section 5.2.3 by culturing the differentiated cells with neurons.
[0148] In certain embodiments, cells expressing at least one microglia marker are differentiated in vitro from differentiated cells obtained according to the methods described in Section 5.2.3 by contacting the differentiated cells with at least one macrophage-promoting cytokine (e.g., to generate cells expressing at least one macrophage marker, e.g., macrophages); and culturing the cells (e.g., macrophages) with neurons. In certain embodiments, the cells (e.g., macrophages) expressing at least one macrophage marker include cells (e.g., primitive macrophages) expressing at least one primitive macrophage marker.
[0149] In certain embodiments, a pure and synchronized population of cells expressing at least one microglial marker is produced / generated by contacting the cells with at least one macrophage-promoting cytokine and culturing the cells with neurons. In certain embodiments, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or at least about 100% of the cells in the cell population express at least one microglial marker. In certain embodiments, contacting the cells with at least one macrophage-promoting cytokine and then culturing the cells with neurons results in a more pure population of microglial cells compared to culturing the cells with neurons without contacting the cells with another macrophage-promoting cytokine.
[0150] Non-limiting examples of microglial markers include CX3CR1, PU.1, CD45, IBA1, P2RY12, TMEM119, SALL1, GPR34, C1QA, CD11B, CD68, CD45, and combinations thereof.
[0151] Non-limiting examples of macrophage markers include CD11B, Dectin, CD14, PU.1, CX3CR1, CD45, and combinations thereof.
[0152] Non-limiting examples of primitive macrophage markers include CX3CR1, CD11B, and combinations thereof.
[0153] Non-limiting examples of neurons include cortical projection neurons, motor neurons, dopaminergic neurons, interneurons, and peripheral sensory neurons.
[0154] Non-limiting examples of macrophage-promoting cytokines include M-CSF, IL-34, GM-CSF, IL-3, and combinations thereof. In certain embodiments, the at least one macrophage-promoting cytokine comprises M-CSF and IL-34.
[0155] In certain embodiments, differentiated cells (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) and macrophages obtained according to the method described in section 5.2.3 are cultured with neurons for at least about 5 days, at least about 10 days, or at least about 15 days. In certain embodiments, differentiated cells and macrophages are cultured with neurons for at least about 5 days, e.g., 4 days. In certain embodiments, differentiated cells and macrophages are cultured with neurons for up to about 5 days, up to about 10 days, or up to about 15 days. In certain embodiments, differentiated cells and macrophages are cultured with neurons for up to about 10 days or about 15 days. In certain embodiments, differentiated cells and macrophages are cultured with neurons for between about 5 days and about 10 days, between about 10 days and about 15 days, or between about 5 days and about 15 days. In certain embodiments, differentiated cells and macrophages are cultured with neurons for between about 5 days and about 10 days. In certain embodiments, the differentiated cells and macrophages are cultured with neurons for about 5 days, or about 10 days, or about 15 days. In certain embodiments, the differentiated cells and macrophages are cultured with neurons for 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or 15 days.
[0156] In certain embodiments, differentiated cells obtained according to the methods described in section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are contacted with at least one macrophage-promoting cytokine for at least about 5 days, at least about 10 days (e.g., at least 9 days or at least 11 days), or at least about 15 days. In certain embodiments, differentiated cells obtained according to the methods described in section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are contacted with at least one macrophage-promoting cytokine for at least about 5 days or at least about 10 days (e.g., at least 11 days). In certain embodiments, differentiated cells obtained according to the methods described in section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are contacted with at least one macrophage-promoting cytokine for up to about 5 days, up to about 10 days, or up to about 15 days. In certain embodiments, differentiated cells obtained according to the methods described in section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are contacted with at least one macrophage-promoting cytokine for up to about 10 days or up to about 15 days. In certain embodiments, differentiated cells obtained according to the methods described in section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are contacted with at least one macrophage-promoting cytokine for about 5 days to about 15 days, for about 5 days to about 10 days, or for about 10 days to about 15 days. In certain embodiments, differentiated cells obtained according to the methods described in section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are contacted with at least one macrophage-promoting cytokine for about 5 days to about 10 days or for about 10 days to about 15 days.In certain embodiments, differentiated cells obtained according to the methods described in section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are contacted with at least one macrophage-promoting cytokine for about 7 days to about 11 days. In certain embodiments, differentiated cells obtained according to the methods described in section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are contacted with at least one macrophage-promoting cytokine for about 5 days or about 10 days. In certain embodiments, differentiated cells obtained according to the methods described in section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are contacted with at least one macrophage-promoting cytokine for 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, or 11 days.
[0157] In certain embodiments, differentiated cells obtained according to the methods described in section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are treated with at least one macrophage-promoting cytokine and at least about 1 ng / ml to about 250 ng / ml, at least about 1 ng / ml to about 100 ng / ml, at least about 1 ng / ml to about 100 ng / ml, at least about 1 ng / ml to about 20 ng / ml, at least about 1 ng / ml to about 15 ng / ml, at least about 1 ng / ml to about 250 ng / ml, at least about 1 ng / ml to about 100 ng / ml, at least about 1 ng / ml to about 2 ... In some embodiments, the antibody is contacted at a concentration of from about 1 ng / ml to about 10 ng / ml, from about 1 ng / ml to about 5 ng / ml, from about 5 ng / ml to about 10 ng / ml, from about 5 ng / ml to about 15 ng / ml, from about 15 ng / ml to about 25 ng / ml, from about 15 ng / ml to about 20 ng / ml, from about 20 ng / ml to about 50 ng / ml, from about 50 ng / ml to about 100 ng / ml, from about 100 ng / ml to about 150 ng / ml, from about 100 ng / ml to about 200 ng / ml, or from about 150 ng / ml to about 200 ng / ml. In certain embodiments, the differentiated cells are contacted with at least one macrophage-promoting cytokine at a concentration of about 5ng / ml to about 15ng / ml, about 15ng / ml to about 25ng / ml, about 40ng / ml to about 60ng / ml, or about 50ng / ml to about 100ng / ml, or about 80ng / ml to about 100ng / ml. In certain embodiments, the differentiated cells are contacted with at least one macrophage-promoting cytokine at a concentration of about 10ng / ml, about 20ng / ml, about 50ng / ml, or about 100ng / ml. In certain embodiments, the differentiated cells are contacted with at least one macrophage-promoting cytokine at any one of the above concentrations every day, every other day, or every two days. In certain embodiments, the differentiated cells are contacted with at least one macrophage-promoting cytokine at a concentration of about 10ng / ml, about 20ng / ml, about 50ng / ml, or about 100ng / ml every day. In certain embodiments, the at least one macrophage-promoting cytokine comprises M-CSF, IL-34, or a combination thereof, hi certain embodiments, the concentration of M-CSF is between about 1 ng / ml and about 100 ng / ml.In certain embodiments, the concentration of M-CSF is about 10 ng / ml or about 20 ng / ml. In certain embodiments, the concentration of IL-34 is between about 5 ng / ml and about 250 ng / ml. In certain embodiments, the concentration of IL-34 is about 100 ng / ml.
[0158] In certain embodiments, differentiated cells (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) obtained according to the method described in section 5.2.3 are cultured in a serum-free culture medium supplemented with at least one macrophage-promoting cytokine. In certain embodiments, the serum-free culture medium comprises about 75% IMDM (Iscorp's Modified Dulbecco's Medium), about 25% F12 medium. In certain embodiments, the serum-free culture medium further comprises B27, L-glutamine.
[0159] In certain embodiments, differentiated cells obtained according to the methods described in Section 5.2.3 (i.e., cells expressing at least one pMac marker and / or cells expressing at least one EMP marker) are cultured in culture medium supplemented with serum and at least one macrophage-promoting cytokine. Cell culture media
[0160] In certain embodiments, the inhibitors, activators and cytokines described above are added to the cell culture medium that contains the cells disclosed herein.Suitable cell culture medium includes, but is not limited to, Knockout Serum Replacement ("KSR") medium, N2 medium, Essential 8 (registered trademark) / Essential 6 (registered trademark) ("E8 / E6") medium, and Neurobasal (NB) medium (e.g., NB medium supplemented with N2 and B-27 (registered trademark) supplement).KSR medium, N2 medium, E8 / E6 medium and NB medium are commercially available.
[0161] KSR medium is a defined serum-free formulation optimized for growing and maintaining undifferentiated hESC cells in culture. The components of KSR medium are disclosed in WO2011 / 149762. In certain embodiments, KSR medium comprises Knockout DMEM, Knockout Serum Replacement, L-glutamine, Pen / Strep, MEM, and 13-mercaptoethanol. In certain embodiments, 1 liter of KSR medium may comprise 820 mL of Knockout DMEM, 150 mL of Knockout Serum Replacement, 10 mL of 200 mM L-glutamine, 10 mL of Pen / Strep, 10 mL of 10 mM MEM, and 55 μM of 13-mercaptoethanol.
[0162] E8 / E6 medium is a feeder-free and xeno-free medium that supports the growth and expansion of human pluripotent stem cells. E8 / E6 medium has been demonstrated to support the reprogramming of somatic cells. Furthermore, E8 / E6 medium can be used as a base for formulating custom media for culturing PSCs. One example of E8 / E6 medium is described in Chen et al., Nat Methods. 2011 May;8(5):424-9, which is incorporated by reference in its entirety. One example of E8 / E6 medium is disclosed in WO15 / 077648, which is incorporated by reference in its entirety. In certain embodiments, E8 / E6 cell culture medium comprises DMEM / F12, ascorbic acid, selenium, insulin, NaHCO3, transferrin, FGF2 and TGFβ. E8 / E6 medium differs from KSR medium in that E8 / E6 medium does not contain active BMP or Wnt components.
[0163] N2 supplement is a chemically defined animal-free supplement used to expand undifferentiated neural stem and progenitor cells in culture.N2 supplement is intended for use in DMEM / F12 medium.The components of N2 medium are disclosed in WO2011 / 149762.In certain embodiments, N2 medium comprises DMEM / F12 medium supplemented with glucose, sodium bicarbonate, putrescine, progesterone, sodium selenite, transferrin, and insulin. In one particular embodiment, 1 liter of N2 medium contains 985 ml of distilled HO with DMEM / F12 powder, 1.55 g glucose, 2.00 g sodium bicarbonate, putrescine (100 μL aliquot of 1.61 g dissolved in 100 mL distilled water), progesterone (20 μL aliquot of 0.032 g dissolved in 100 mL 100% ethanol), sodium selenite (60 μL aliquot of 0.5 mM solution in distilled water), 100 mg transferrin, and 25 mg insulin in 10 mL of 5 mM NaOH. 5.3 Compositions Comprising Microglial Cells
[0164] The present disclosure provides compositions comprising a population of differentiated microglial cells produced by the in vitro differentiation methods described herein, for example, in Section 5.2.
[0165] The presently disclosed subject matter further provides a composition comprising a population of in vitro differentiated cells, wherein at least about 50% (e.g., at least about 55%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%) of the cells in the population express at least one microglial marker, and less than about 25% (e.g., less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1%, less than about 0.5%, or less than about 0.1%) of the cells in the population express at least one marker selected from the group consisting of stem cell markers, mesoderm progenitor markers, primary hematopoietic progenitor markers, EMP markers, premacrophage markers, and macrophage markers.
[0166] Non-limiting examples of stem cell markers include OCT4, NANOG, SSEA4 and SSEA3.
[0167] Non-limiting examples of mesodermal progenitor markers include brachyury, KDR, and combinations thereof.
[0168] Non-limiting examples of primary hematopoietic progenitor markers include KDR, CD235A, and combinations thereof.
[0169] Non-limiting examples of EMP markers include Kit, CD41, CD235A, CD43, and combinations thereof.
[0170] Non-limiting examples of pre-macrophage markers include CD45, CSF1R, and combinations thereof.
[0171] Non-limiting examples of microglial markers include CX3CR1, PU.1, CD45, IBA1, P2RY12, TMEM119, SALL1, GPR34, C1QA, CD11B, CD68, CD45, and combinations thereof.
[0172] Non-limiting examples of macrophage markers include CD11B, Dectin, CD14, PU.1, CX3CR1, CD45, and combinations thereof.
[0173] In certain embodiments, the composition comprises about 1×10 4 From about 1×10 10 , about 1×10 4 From about 1×10 5 , about 1×10 5 From about 1×10 9 , about 1×10 5 From about 1×10 6 , about 1×10 5 From about 1×10 7 , about 1×10 6 From about 1×10 7 , about 1×10 6 From about 1×10 8 , about 1×10 7 From about 1×10 8 , about 1×10 8 From about 1×10 9 , about 1×10 8 From about 1×10 10 , or approximately 1 × 10 9 From about 1×10 10 In certain embodiments, the composition comprises about 1×10 5 From about 1×10 7 The presently disclosed stem cell-derived microglial cells include:
[0174] In certain embodiments, the composition is frozen. In certain embodiments, the composition may further comprise at least one cryoprotectant, such as, but not limited to, dimethylsulfoxide (DMSO), glycerol, polyethylene glycol, sucrose, trehalose, dextrose, or combinations thereof.
[0175] In certain non-limiting embodiments, the composition further comprises a biocompatible scaffold or matrix, for example, a biocompatible three-dimensional scaffold that promotes tissue regeneration when cells are implanted or grafted into a subject. In certain non-limiting embodiments, the biocompatible scaffold comprises an extracellular matrix material, a synthetic polymer, a cytokine, a collagen, a polypeptide or protein, a polysaccharide including fibronectin, laminin, keratin, fibrin, fibrinogen, hyaluronic acid, heparin sulfate, chondroitin sulfate, agarose or gelatin, and / or a hydrogel. (See, for example, U.S. Patent Application Publication Nos. 2015 / 0159135, 2011 / 0296542, 2009 / 0123433, and 2008 / 0268019, which are incorporated by reference in their entirety.)
[0176] In certain embodiments, the composition is a pharmaceutical composition comprising a pharma- ceutical acceptable carrier.The composition can be used to regenerate the peripheral nervous system (hereinafter "PNS") and / or the central nervous system (hereinafter "CNS") to prevent and / or treat microglial cell-related disorders.
[0177] The presently disclosed subject matter also provides devices comprising the differentiated cells disclosed herein or compositions comprising same. Non-limiting examples of devices include syringes, fine glass tubes, stereotactic needles and cannulas. 5.4 Treatment method
[0178] In vitro differentiated microglial cells can be used to treat neurodegenerative diseases. The present disclosure provides a method for preventing and / or treating neurodegenerative diseases.Non-limiting examples of neurodegenerative diseases include Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, schizophrenia, glioblastoma, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis (MS).
[0179] In certain embodiments, the method comprises administering to a subject an effective amount of at least one of the following: (a) a population of differentiated microglial cells described herein; and (b) a composition comprising such differentiated microglial cells.
[0180] Additionally, the presently disclosed subject matter provides uses of at least one of the following: (a) a population of differentiated microglial cells described herein; and (b) a composition comprising such differentiated microglial cells, for preventing and / or treating a neurodegenerative disease.
[0181] The stem cell-derived microglial cells disclosed herein or compositions comprising the same may be administered or provided to a subject systemically or directly. In certain embodiments, the stem cell-derived microglial cells disclosed herein or compositions comprising the same are directly injected into an organ of interest (e.g., an organ affected by a microglial cell deficiency-associated disorder). The stem cell-derived microglial cells disclosed herein or compositions comprising the same may be administered (injected) directly into any part of the subject's body that has active nerves, including, but not limited to, the brain.
[0182] The stem cell-derived microglial cells disclosed herein or compositions comprising the same may be administered in any physiologically acceptable vehicle. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier and the stem cell-derived microglial cells disclosed herein are also provided. The stem cell-derived microglial cells disclosed herein or compositions comprising the same, or a pharmaceutically acceptable carrier may be administered via local injection, orthotropic (OT) injection, systemic injection, intravenous injection, or parenteral administration. In certain embodiments, the stem cell-derived microglial cells disclosed herein or compositions comprising the same are administered to a subject via local injection.
[0183] The presently disclosed stem cell-derived microglial cells or compositions comprising the same may be conveniently provided as a sterile liquid preparation, e.g., an isotonic aqueous solution, suspension, emulsion, dispersion, or viscous composition, which may be buffered to a selected pH. Liquid preparations are usually easier to prepare than gels, other viscous compositions, and solid compositions. In addition, liquid compositions are somewhat more convenient to administer, particularly by injection. Viscous compositions, on the other hand, may be formulated within an appropriate viscosity range to prolong contact time with a particular tissue. A liquid or viscous composition may contain a carrier, which may be, for example, a solvent or dispersion medium, including water, saline, phosphate buffered saline, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), and suitable mixtures thereof. Sterile injectable solutions may be prepared by incorporating the presently disclosed subject matter, e.g., compositions comprising the presently disclosed stem cell-derived microglial cells, in the required amount of an appropriate solvent with various amounts of other ingredients, as needed. Such compositions may be additive mixtures containing suitable carriers, diluents, or excipients, such as sterile water, saline, glucose, dextrose, and the like. The compositions may also be lyophilized. Depending on the route of administration and the desired preparation, the compositions may contain auxiliary substances, such as wetting agents, dispersing or emulsifying agents (e.g., methylcellulose), pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, coloring agents, and the like. Standard texts, such as "REMINGTON'S PHARMACEUTICAL SCIENCE", 17th edition, 1985, may be consulted for the preparation of suitable preparations without undue experimentation, which text is incorporated herein by reference.
[0184] Various additives that enhance the stability and sterility of the composition may be added, including antimicrobial preservatives, antioxidants, chelating agents, and buffers. Prevention of microbial action can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. Prolonged absorption of the injectable pharmaceutical form may be achieved by using absorption delaying agents, such as alum inurn monostearate and gelatin. However, according to the subject matter disclosed herein, any vehicle, diluent, or additive used must be compatible with the stem cell-derived microglial cells disclosed herein or compositions containing them.
[0185] Those skilled in the art will recognize that the components of the composition should be selected to be chemically inert and will not affect the viability or efficacy of the stem cell-derived microglial cells disclosed herein, which will not be a problem for those skilled in the art of chemical and pharmaceutical principles, or will be easily circumvented by reference to standard textbooks or by simple experimentation (without undue experimentation) from this disclosure and the documents cited herein.
[0186] In certain non-limiting embodiments, the microglial cells described herein are included in a composition, which further comprises a biocompatible scaffold or matrix, e.g., a biocompatible three-dimensional scaffold that promotes tissue regeneration when the cells are implanted or grafted into a subject. In certain non-limiting embodiments, the biocompatible scaffold comprises an extracellular matrix material, a synthetic polymer, a cytokine, a collagen, a polypeptide or protein, a polysaccharide including fibronectin, laminin, keratin, fibrin, fibrinogen, hyaluronic acid, heparin sulfate, chondroitin sulfate, agarose or gelatin, and / or a hydrogel (see, e.g., U.S. Patent Nos. 2015 / 0159135, 2011 / 0296542, 2009 / 0123433, and 2008 / 0268019, which are incorporated by reference in their entirety).
[0187] An "effective amount" (or "therapeutically effective amount") is an amount sufficient to affect beneficial or desired clinical results upon treatment. An effective amount may be administered to a subject in at least one dose. In terms of treatment, an effective amount is an amount sufficient to palliate, improve, stabilize, reverse or delay the progression of a neurodegenerative disease, or reduce the pathological consequences of a neurodegenerative disease. An effective amount is generally determined by a physician on a case-by-case basis and within the skill of a person of ordinary skill in the art. Several factors are typically considered when determining the appropriate dosage to achieve an effective amount. These factors include the age, sex and weight of the subject, the condition being treated, the severity of the condition, and the form and effective concentration of the cells being administered.
[0188] In certain embodiments, an effective amount of the stem cell-derived microglial cells disclosed herein is an amount sufficient to prevent a neurodegenerative disease and / or an amount sufficient to treat a neurodegenerative disease (e.g., to delay progression of, alleviate and / or reduce symptoms). The amount of stem cell-derived microglial cells disclosed herein to be administered will vary for each subject being treated. In certain embodiments, an effective amount of the stem cell-derived microglial cells disclosed herein is an amount sufficient to prevent a neurodegenerative disease and / or an amount sufficient to treat a neurodegenerative disease (e.g., to delay progression of, alleviate and / or reduce symptoms). The amount of the stem cell-derived microglial cells disclosed herein to be administered will vary for each subject being treated. In certain embodiments, an effective amount of the stem cell-derived microglial cells disclosed herein is an amount sufficient to prevent a neurodegenerative disease and / or to treat a neurodegenerative disease (e.g., to delay progression of, alleviate and / or reduce symptoms).4 From about 1×10 10 , about 1×10 4 From about 1×10 5 , about 1×10 5 From about 1×10 9 , about 1×10 5 From about 1×10 6 , about 1×10 5 From about 1×10 7 , about 1×10 6 From about 1×10 7 , about 1×10 6 From about 1×10 8 , about 1×10 7 From about 1×10 8 , about 1×10 8 From about 1×10 9 , about 1×10 8 From about 1×10 10 , or approximately 1 × 10 9 From about 1×10 10 In one particular embodiment, about 1×10 stem cell-derived microglial cells as disclosed herein are administered to a subject. 5 From about 1×10 7 The presently disclosed stem cell-derived microglial cells are administered to the subject. The exact determination of what will be considered an effective dose may be based on individual factors for each subject, including the size, age, sex, weight, and condition of the particular subject. The dosage can be easily ascertained by those skilled in the art from this disclosure and knowledge in the art.
[0189] In certain embodiments, the method for preventing and / or treating a neurodegenerative disease comprises administering to a subject an effective amount of a colony-stimulating factor (CSF).Furthermore, the presently disclosed subject matter provides for the use of a CSF to prevent and / or treat a neurodegenerative disease.
[0190] Non-limiting examples of CSFs include granulocyte-macrophage colony-stimulating factor (GM-CSF), M-CSF, and IL-34. In certain embodiments, the CSF is GM-CSF, also known as colony-stimulating factor 2 (CSF2).
[0191] CSF can reduce complement C3 released from microglial cells, and as a result, CSF can be used to prevent and / or treat neurodegenerative diseases (e.g., Alzheimer's disease). 5.5 Kit
[0192] The presently disclosed subject matter provides a kit for inducing differentiation of stem cells. In certain embodiments, the kit comprises: (a) at least one inhibitor of Wnt signaling; (b) at least one activator of Wnt signaling; (c) at least one hematopoietic promoting cytokine; and (d) a neuron. In certain embodiments, the kit comprises:
[0193] (e) at least one macrophage-promoting cytokine. In certain embodiments, the kit further comprises (f) instructions for inducing differentiation of the stem cells into cells expressing at least one microglial marker.
[0194] In certain embodiments, the instructions include contacting the stem cells with inhibitors, activator cytokines, and molecules as described in the methods of the present disclosure (see Section 5.2, above).
[0195] In certain embodiments, the present disclosure provides a kit comprising an effective amount of the population of stem cell-derived microglial cells disclosed herein or a composition comprising the same in unit dosage form.In certain embodiments, the kit comprises a sterile container comprising a therapeutic composition; such container may be a box, an ampoule, a bottle, a vial, a tube, a bag, a pouch, a blister pack, or other suitable container form known in the art.Such container may be made of plastic, glass, laminated paper, metal foil, or other suitable material for holding pharmaceuticals.
[0196] In certain embodiments, the kit includes instructions for administering the population of stem cell-derived microglial cells disclosed herein or a composition comprising the same to a subject suffering from a neurodegenerative disease. The instructions may include information about the use of the cells or composition to treat and / or prevent a neurodegenerative disease. In certain embodiments, the instructions include at least one of the following: description of the therapeutic agent; dosing schedule and administration for treating or preventing a neurodegenerative disease or a symptom thereof; precautions for use; warnings; indications; counter-indications; overdosage information; side effects; animal pharmacology; clinical studies; and / or a description of references. The instructions may be printed directly on the container (if present), printed as a label to be affixed to the container, or printed as a separate sheet, pamphlet, card, or folder in or attached to the container. 5.6 Methods for screening therapeutic compounds
[0197] The stem cell-derived microglial cells disclosed herein can be used to model neurodegenerative diseases (e.g., Alzheimer's and amyotrophic lateral sclerosis (ALS)).
[0198] The stem cell-derived microglial cells disclosed herein can also serve as a platform for screening candidate compounds that can overcome the cellular phenotype of the disease. The ability of a candidate compound to alleviate a neurodegenerative disease may be determined by assaying the ability of the candidate compound to rescue the physiological or cellular defects that lead to the neurodegenerative disease.
[0199] In certain embodiments, the method includes the steps of (a) contacting a population of microglial cells disclosed herein with a test compound, the microglial cells being derived from stem cells obtained from a subject with a neurodegenerative disease; and (b) measuring the functional activity of the microglial cells, where a change in the functional activity of the microglial cells indicates that the test compound is likely to be able to treat the neurodegenerative disease. The change may be a decrease or an increase. In certain embodiments, the change is a decrease. In certain embodiments, the microglial cells are contacted with the test compound for at least about 24 hours (1 day), about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, or about 10 days. In certain embodiments, the microglial cells are contacted with the test compound for at least about 24 hours (1 day).
[0200] In certain embodiments, the functional activity of microglial cells comprises the release of complement C3. In certain embodiments, the change is a decrease. An increase in complement C3 has been shown in mouse models of Alzheimer's and is involved in the abnormal pruning of synapses in disease conditions. In certain embodiments, a decrease in the complement C3 released from microglial cells indicates that the test compound is likely to treat neurodegenerative diseases, such as Alzheimer's disease or ALS.
[0201] The present inventors have found that wild-type stem cell-derived microglial cells have selectivity for pathogenic amyloid-beta-42 over harmless amyloid-beta-40. In certain embodiments, the functional activity of microglial cells comprises amyloid-beta phagocytosis by microglial cells. In certain embodiments, the change is an increase. In certain embodiments, an increase in amyloid-beta phagocytosis by microglial cells indicates that the test compound is likely to be able to treat neurodegenerative diseases, such as Alzheimer's disease.
[0202] The inventors found that microglial cells express the highest levels of C9ORF22, a gene mutated in a genetic form of early-onset ALS. The inventors also found that complement C3 release is increased in C9ORF22 mutant stem cell-derived microglial cells. Activated microglia can induce neurotoxic reactive astrocytes that can induce neurotoxicity in motor neurons. Liddelow et al. al., "Neurotoxic reactive astrocytes are induced by activated microglia", Nature (26 January 2017);541:481-7 487. In certain embodiments, the method includes (a) contacting a test compound with a composition comprising a population of microglial cells, astrocytes, and a population of neurons disclosed herein; and (b) measuring neurotoxicity of the neurons, where a reduction or decrease in neurotoxicity of the neurons after contact with the test compound indicates that the test compound is likely capable of treating a neurodegenerative disease. In certain embodiments, the neurons are motor neurons, and the method is used to screen compounds for treating ALS. Non-limiting examples of neurotoxicity of neurons include synapse loss, axonal degeneration, and apoptosis. In certain embodiments, the composition is contacted with the test compound for at least about 24 hours (1 day), about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, or about 10 days. In certain embodiments, the composition is contacted with the test compound for at least about 4 days. EXAMPLES
[0203] The presently disclosed subject matter will be better understood by reference to the following examples, which are provided by way of illustration of the presently disclosed subject matter, but not by way of limitation. 6.1 (Example 1) Differentiation of Microglia from Human Stem Cells
[0204] Inhibiting Wnt signaling biases early mesodermal cells from the posterior primitive streak, generating KDR+CD235a+ primary hematopoietic precursors (Sturgeon et al., Nat.Biotechnol.(2014);32, 554-561). These precursors will initiate primary hematopoiesis in the yolk sac and give rise to early EMPs. In this microglial differentiation scheme, we applied Wnt inhibition to induce primary hematopoiesis from hPSCs in a monolayer strategy. Notably, we showed that 18 h of Wnt activation by the Wnt agonist Chir099021 led to early mesoderm characterized by brachyury (T) by immunofluorescence (Figure 1A). These cells were also KDR+ and CD235a+ (primary hematopoietic precursors) by day 4 of differentiation by flow cytometry. The concentration and timing of Chir099021 exposure in the differentiation scheme was optimized, with 18 h exposure at 3 μM followed by Wnt inhibition via IWP2 at 3 μM resulting in the highest percentage of primary hematopoietic progenitors (KDR+CD235a+) by flow cytometry (Figure 1B). Next, the present example developed a schedule for hemogenic endothelial and hematopoietic cells. Hemogenic endothelial cells were sorted using KDR + CD235A + This occurred one day after reseeding of primary hematopoietic progenitors. These cells yielded hematopoietic cells in suspension over the course of 7 days in culture, which gradually increased in number in the culture (Figure 2). To verify hemogenic endothelial cells by VE-cadherin+ staining, one day after sorting, the cells were positive for VE-cadherin by immunofluorescence, confirming that they were hemogenic endothelial cells, and the cells in suspension had the characteristic small nuclei of hematopoietic cells (Figure 3). Five days after reseeding, the Kit + Cells emerged that were early erythromyeloid progenitors (EMPs), the precursors of microglia. These cells were then identified by flow cytometry as CD45 +, indicating that hematopoietic commitment was complete (Figure 4). When a mixed population of EMPs was present 8 days after sorting the cultures, these cells were identified as microglia and macrophage precursors, rather than mature macrophages (Figure 6). Only a small percentage expressed mature macrophage markers, such as CX3CR1, CD14, Cd11b, and MRC. The majority of cells expressed CD45, indicating that they were committed to the hematopoietic lineage. All markers were confirmed by flow cytometry.
[0205] Eight days after sorting, cells in suspension containing pMac were cultured with neurons, yielding early microglial cells by only four days of coculture (Figure 7). These cells were identified using Iba1+ and Pu.1+ staining. CD45 + All cells that were Pu.1 + None of the hematopoietic cells (CD45 + It was shown that the microglial cells (represented by Iba1+ by immunofluorescence) were also committed to the myeloid / microglial lineage (represented by PU.1), indicating that this strategy by immunofluorescence is highly efficient. Microglial cells (Iba1+ by immunofluorescence) still remained persisted in the co-culture 14 days after co-culture with cortical neurons, indicating that Iba1+ cells were stable in the culture (Figure 8). Microglial cells (Iba1+ by immunofluorescence) were also committed to the myeloid / microglial lineage (represented by PU.1), indicating that the Iba1+ cells were stable in the culture (Figure 8). + , PU.1 + ) still persisted in co-culture with neurons after 21 days in culture (FIG. 9).
[0206] In a second strategy to generate microglia, EMPs were matured into macrophages with 10% serum and M-CSF and IL-34. They developed the mature macrophage marker CD11b by day 4 in culture and mature spindle morphology by day 11 (Figure 10). After 11 days, all cells maintained in culture in serum and M-CSF and IL-34 were CD45 +pMacs were also positive for mature macrophage markers, such as CX3CR1, CD14, CD11b, and dectin, by flow cytometry analysis (Figure 11). pMacs could also be matured to macrophages without serum, using IMDM / F12 / N2 / B27 instead of serum and M-CSF and IL-34 (Figure 12). Addition of IL-34 to M-CSF increased the yield by promoting cell division. Addition of GM-CSF caused the cells to divide similarly, but the resulting cells appeared more granular and activated. Co-culturing macrophage cells with neurons yielded microglial cells with branched morphology and increased Iba1 immunofluorescence staining (Figure 13). Since Iba1 was increased in microglial cells from macrophages, the cells were transitioning to a microglial identity via co-culturing with neurons. Co-cultured pMac-derived microglia (EMP co-cultures) and pMac-macrophage-derived microglia (EMP-macrophage co-cultures) share expression of key microglial genes with human fetal microglia (Figure 14). Quantitative PCR of RNA from two different strategies to derive microglia shared gene expression of a panel of key microglial genes with RNA from human fetal microglia (a commercially available source). In contrast, monocyte-derived macrophages, which represent peripheral macrophages, did not express these markers. Notably, when EMP-derived macrophages were cultured alone, they downregulated the key microglial genes TMEM119 and SALL1, indicating that co-culture was required to maintain microglial identity.
[0207] In summary, this example applies Wnt inhibition in a monolayer strategy to induce primary hematopoiesis from hPSCs (Figure 5). First, this example induces hPSCs to be brachyurinary inducible using Wnt activation with the small molecule CHIR99021. + (T +) into posterior primitive streak early mesodermal cells. We then induced these cells to robustly generate KDR+CD235a+ primary hematopoietic progenitors by blocking Wnt signaling with the small molecule inhibitor IWP2. We show that rigorous treatment with CHIR99021 for 18 hours followed by IWP2 treatment resulted in a significant proportion of KDR+CD235a+ primary hematopoietic progenitors. + CD235A + In a previous study, they determined that Wnt activation was the only condition that allowed the development of mesoderm cells. + CD235A + It does not challenge the patterning towards precursors and, as a result, does not limit the treatment period to 18 hours, which in this case was determined to significantly reduce the potential for forming this population. + CD235A + In a previous study in which the precursors were identified as primary hematopoietic progenitors, the authors acknowledged that this population arose by the embryoid body method, in which endogenous signaling plays a major role, and therefore Wnt inhibition alone could be used (Sturgeon et al., Nat. Biotechnol. (2014); 32, 554-561). As a result, the present example demonstrates the ability to induce KDR hematopoietic stem cells by first inducing mesoderm using an 18-hour Wnt activation treatment, followed by Wnt inhibition. + CD235A + Primary hematopoietic progenitors have been derived from hPSCs in a novel manner in a defined monolayer system.
[0208] Next, this example is KDR + CD235A + Primary hematopoietic progenitors are driven to form EMPs by the addition of a cocktail of hematopoietic-promoting cytokines: in a stepwise manner over 8 days, first VEGF / FGF2 is added to induce VE-cadherin+ hemogenic endothelial cells, then SCF, IL-6, IL-3, and TPO to induce CD34+, followed by CD45 +The floating CD45+ pMacs were then harvested on day 8 of culture and either co-cultured with neurons to directly migrate to microglia or matured to macrophages and then co-cultured with neurons to migrate to microglia. The first method is particularly novel in that it is the only method to show that microglial cells can develop directly from early pMacs within 4 days when co-cultured with neurons, as in vivo development in mice (Mass et al., Science (2016); 353(6304) aaf4238).
[0209] Existing strategies for generating human microglial cells in vitro do not follow this developmental paradigm and fail to initially pattern them towards primary hematopoietic progenitors. These strategies start from peripheral monocytes that arise from secondary hematopoiesis (Noto et al., Neuropathol. Appl. Neurobiol. (2014); 40, 697-713;Ohgidani et al., Sci. Rep. (2014); 4, 4957), and as a result, microglial cells are either not obtained in vivo or use embryoid body approaches that are not prepatterned for primary hematopoiesis and are a black box with regard to developmental cell fate decisions (Etemad et al. al., Neurosci. (2012); 209, 79-89;Hinze et al., Inflamm. (2012); 9, 12;Lachmann et al., Stem Cell Reports (2015);4, 282-296;Noto et al., Neuropathol. Appl. Neurobiol. (2014); 40, 697-713;Ohgidani et al., Sci. Rep. (2014); 4, 4957;van Wilgenburg et al., PLoS One (2013); 8.;Muffat et al., Nature Medicine (2016); 22(11), Among the monolayer protocols for deriving microglia-like cells from hPSCs (Abud et al., Neuron, (2017); 94(2), 278-293; Takata et al., Immunity. (2017); 47(1), 183-198), the cells were again derived from primary hematopoietic KDR + CD235A + These strategies have not been designed to pattern cells, and as a result there is no way to determine whether these strategies pass through early EMPs that are true precursors of microglia, or late EMPs that are precursors of definitive hematopoiesis. Furthermore, all these strategies involve the transfection of CD45 cells prior to co-culture with neurons. + We are the first to generate fully differentiated macrophages from pMacs (even if co-cultured), and therefore do not represent the in vivo developmental trajectory of the progenitor cells (pMacs) that first colonize the brain and give rise to tissue-resident microglia (Mass et al., Science (2016);353(6304), aaf4238). The present strategy is novel in that it uses a stepwise developmental paradigm that recapitulates primary yolk sac hematopoiesis, isolates pMacs before they mature into macrophages, and cultures these cells in the neural niche in vitro to generate bona fide human microglial cells in as little as 16 days.
[0210] An exemplary protocol for differentiating microglia from human stem cells is provided below: Stage I: pMac Production (Serum-Free) 1) Day 0: ES cells were plated in ABC medium in either 24-well or 6-well tissue culture plates coated with 1:30 Matrigel. * 60,000 cells / cm^ in culture medium 2 Sow with +Y. 2) Day 1: After 18 hours, change the medium to ABi medium. Cells should be T+ (Brachyury+). 3) Day 2: Change medium to ABi+FGF2. 4) Day 3: 60,000 cells / cm^ in VEGF / FGF2 medium + Y on Matrigel 2 Split and seed the cells at 100°C. At least 30% of the cells are KDR. + CD235A + It should be. 5) Day 4: Y-Remove drug, leave VEGF / FGF2 in place. 6) Day 5: Add Cyto 1 medium. 10-20% of the cells are Kit + It must be (EMP). 7) Day 6: Check whether small round cell colonies have formed. 8) Day 7: Add Cyto 2 medium. 9) Day 8: Round cells should be confluent. Collect cells in suspension and spin down. Cultures are classified as VE-cadherin+ hemogenic endothelial cells, and Kit+ (EMP) or Kit+ (EMP) or Kit+ (EMP) hemogenic endothelial cells. - CD45 + CSF1R + The suspension should contain round cells that are (pMac).
[0211] Step IIa. Direct conversion of neural co-cultures (serum-free) to microglial cells 1) Collect only the suspension cells from the day 8 culture and spin them down. 2) Seed suspension cells at a 1:5 ratio with neurons in microglia medium #1. 3) Change the medium every other day. Four days later, many Pu.1 + CD45 + , Iba1 + , CX3CR1 + Microglial cells should already be present in the culture. 4) Cells should be ready to assay after 10-14 days in co-culture. CX3CR1 + When sorted by P2RY12, microglial cells + , Tmem119 + , Sall1+ , GPR34 + , and C1QA + It should be. Stage IIb. Differentiation into macrophage cells followed by co-culture with neurons
[0212] 1) Suspension cells are plated 1:2 in RPMI medium on TC-treated plastic. 2) If the medium is changed every other day (MWF) they can be left in medium over the weekend. 3) After 11 days, cells should look elongated and granular. Treat cells with Accutase for 10 minutes and seed with neurons at a 1:5 ratio. Cells are Cd11b + , Dectin + , CD14 + (mature macrophages). 4) Culture the cells with neurons in microglia co-culture medium and perform the assay after 10-14 days.
[0213] Table 1 provides the concentrations and concentration ranges of certain components in the cell culture medium used in this example. [Table 1-1] [Table 1-2] 6.2 (Example 2): Application of generated microglial cells
[0214] hPSC-derived microglia derived by this developmental strategy will be useful for investigating the interactions between microglia and neurons in vitro during disease modeling. These mixed cultures may be utilized for multi-cell type drug screening where cell exchange is targeted rather than individual cell types alone (Hoing et al., Cell Stem Cell (2012);11, 620-632;Schwartz et al., Proc. Natl. Acad. Sci. USA (2015); 112(40), 12516-21).
[0215] Microglial cells derived from this disclosure can be co-cultured with astrocytes to create a system containing three components of the CNS: neurons, microglia, and astrocytes. Microglia were tagged with RFP and astrocytes with GFAP+ by immunofluorescence (Figures 15 and 16). The avian culture system can be used to study interactions between cell types. Inflammatory stimuli, or disease conditions that induce inflammatory stimuli, affect both microglia and astrocytes with crosstalk (Figure 17). This crosstalk is a feedback or feed-forward loop that can subsequently result in toxicity to neurons. This interaction can be studied using the hPSC-derived microglia disclosed here in avian cultures with hPSC-derived astrocytes and neurons to explore a fully human system in vitro. LPS stimulation in avian cultures resulted in reactive cytokine release (Figure 18). One microgram / mL of LPS was added to cells in avian cultures containing microglia, astrocytes, and neurons, or to cultures containing only microglia and neurons, or only astrocytes and neurons, or only neurons. Because microglia was the only cell type expressing the receptor for LPS (TLR4), only cultures containing it responded to LPS, but avian cultures showed increased release of C3 compared to cultures containing only microglia and neurons. The effect may be due to reactive cytokines from activated microglia feeding back to astrocytes, resulting in their reactivity and release of astrocytic C3. LPS-stimulated avian and microglia / neuron-only cultures also secreted other reactive cytokines, including IL-6, TNFα, GM-CSF, IL1B, and IFNγ. Cytokines were measured via ELISA.
[0216] This provides a powerful tool since microglia are involved in the pathogenesis of many diseases, both neurodevelopmental and neurodegenerative (some examples are schizophrenia, Alzheimer's, Parkinson's, glioblastoma.) Furthermore, the microglial cells may also be used to treat various diseases by transplanting them into the brain of patients.
[0217] hPSC-derived microglia were used to model two neurodegenerative diseases, Alzheimer's and amyotrophic lateral sclerosis (ALS). When hPSC-derived microglia and Alzheimer's iPSC-derived neurons were co-cultured, microglial activation was observed in the disease cultures, particularly with respect to increased complement C3 release. The present example found that, compared to H9 controls, tri-cultures containing Alzheimer's neurons showed C3 enhancement and increased C3 release (Figure 19). Tri-cultures co-cultured with APP / SWe mutant neurons, a genetic model for familial Alzheimer's disease, showed increased C3 compared to cultures with microglia and neurons only, and levels were increased compared to cultures in which neurons were derived from the H9 control embryonic stem cell line. In contrast, C3 levels were not increased in tri-cultures compared to microglia / neuron cultures in the H9 control, indicating that enhancement of C3 did not occur without disease stimuli. C3 was measured via ELISA. Furthermore, GM-CSF reduced C3 release in all cultures, both Alzheimer's and control (Figure 20). Cell counts by immunofluorescence were also comparable between GM-CSF and control conditions, indicating that this effect was not due to a reduction in microglial cells. Amyloid-beta burden was reduced in microglial co-cultures with selectivity for amyloid-42 peptide (Figure 21). Co-cultures of microglial cells with Alzheimer's neurons showed a reduction in total amyloid beta via ELISA, and specifically a reduction in amyloid-beta 42 peptide when compared to the 40 and 38 peptides. Increased fluorescence of 42-488 inside microglial cells indicated increased uptake (Figure 22). To assay whether microglial cells phagocytose amyloid-beta, fluorescently labeled amyloid-beta 42 peptide was injected into microglial cells using Alexa fluor ELISA. We used 4888 and found by immunofluorescence that after 2 hours, the majority of the microglial cells had amyloid beta 42 in them. On the other hand, amyloid-beta 40 (labeled by 555) was not found as brightly in the microglial cells, indicating that it was not phagocytosed as efficiently. This demonstrated the selectivity for amyloid beta 42 by the microglial cells. Switching the fluorophore yielded similar results, where amyloid-beta 42 was taken up by the microglial cells to a greater extent (Figure 23). Switching the fluorophores representing amyloid 42 and 40 ensured that the effect of increased brightness of 42 in the cells was not due to an effect of technical fluorophore brightness. Even with the switched fluorophores, 42 is labeled by 555 and 40 by 488 in this experiment, but there was still more brightness of 42 present in the microglial cells by immunofluorescence, confirming previous results that microglial cells selectively phagocytosed amyloid-beta 42. FACS analysis showed selectivity for amyloid-42 at baseline and increased uptake upon GM-CSF treatment (Figure 24). GM-CSF treatment increased phagocytosis of amyloid-beta 42 and 40 in microglial cells, and the number of cells bearing amyloid-beta peptides within them was quantified using flow cytometry.
[0218] In summary, an increase in complement C3 has been shown in mouse models of Alzheimer's and is involved in the abnormal pruning of synapses in disease settings. We investigated cytokines that could suppress this increase in C3 from microglia in our co-cultures and identified GM-CSF as a potential candidate. We also studied amyloid-beta phagocytosis by hPSC-derived microglial cells. We found that wild-type hPSC-derived microglial cells have selectivity for pathogenic amyloid-beta-42 over harmless amyloid-beta-40, and we generated a CRISPR knockout of the microglial receptor TREM2 to see if it is involved in this selectivity. We plan to perform a CRISPR screen of candidate immune genes and cell surface receptors to determine which genes and pathways are most closely involved in amyloid-beta phagocytosis.
[0219] Our second disease model using hPSC-derived microglia is ALS. We found that ALS microglia and astrocytes showed increased complement C3 release at baseline (Figure 25). SOD1 mutant iPSC-derived ALS astrocytes and microglia were cultured alone or together and showed higher C3 levels relative to syngeneic versus wild-type control cell line-derived astrocytes or microglia quantified by ELISA. This indicates that C3 reactivity is not unique to Alzheimer's and that the system disclosed here can be used to study other neurodegenerative diseases where loops between microglia, astrocytes, and neurons likely also exist.
[0220] The present example noted that microglial cells expressed the highest levels of C9ORF22, a gene mutated in a genetic form of early-onset ALS. The present example also noted that complement C3 release was increased in C9ORF22 mutant iPSC-derived microglial cells, and the present example tested whether these cells, in conjunction with iPSC-derived astrocytes, are neurotoxic to iPSC-derived motor neurons. The present example plans to perform drug screening using the present iPSC-derived microglia, astrocyte, and neuron triculture system in an ALS model to find candidates that can rescue this neurotoxicity by acting on the neuroinflammatory system rather than on neurons alone. 6.3 (Example 3): Fully defined human PSC-derived microglia and chicken culture systems reveal cell type-specific enhancement of complement production in a model of Alzheimer's disease.
[0221] Aberrant inflammation in the central nervous system (CNS) has been implicated as a key player in the pathogenesis of human neurodegenerative diseases. However, the specific contribution of each cell type to the neuroinflammatory axis in vivo remains unclear, with specific species differences in key signaling pathways further complicating the challenge.
[0222] In recent years, neuroinflammation has been increasingly implicated in the progression of various neurodegenerative disorders, e.g. Alzheimer's (Deczkowska, A. et al. Cell 173, 1073-1081 (2018); Keren-Shaul, H. et al. Cell 169 (2017)), Parkinson's (Lecours, C. et al. Front Cell Neurosci 12 (2018);Olanow, CW et al. Brain 142, 1690-1700 (2019)), amyotrophic lateral sclerosis (ALS) (Geloso, MC et al. Front Aging Neurosci 9 (2017)), as well as in aging. Microglia are considered to be key players in triggering the inflammatory situation in the brain, which may promote or exacerbate disease pathology. Other glial cells, e.g., astrocytes, may interact with microglia and further contribute to aberrant inflammation, resulting in neurotoxicity (Liddelow, SA et al. Nature 541, 481-487 (2017);Rostalski, H. et al. Front Neurosci 13 (2019)). However, analyzing cellular crosstalk in vivo and understanding species-specific differences in neuroinflammatory responses (Smith, et al., Trends Neurosci 37, 125-135 (2014)) have been major challenges in the field. Human pluripotent stem cell (hPSC) technology has the potential to overcome both these challenges and present a defined, scalable, fully human platform to study neuroinflammation. An essential requirement for such hPSC-based models is a differentiation strategy that can reproducibly generate pure populations of microglia, astrocytes, and neurons in a synchronous, efficient, and timely manner.Protocols based on dual SMAD inhibition (Chambers, SM et al. Nat Biotechnol 27, 275-280 (2009);Qi, Y. et al. Nat Biotechnol 35, 154-163 (2017)) allow efficient production of highly pure neural progenitors and postmitotic neurons from hPSCs. Similarly, a strategy for rapidly deriving pure populations of astrocytes from hPSCs was recently reported (Tchieu, J. et al. Nat Biotechnol 37, 267-275 (2019)). In contrast, several protocols have been published for generating microglia-like cells from hPSCs (Muffat, J. et al. Nat Med 22, 1358-1367 (2016);Abud, EM et al. Neuron 94, 2019). 278-293.e279 (2017);Douvaras, P. et al. Stem Cell Reports 8, 1516-1524 (2017);Haenseler, W. et al. Stem Cell Reports 8, 1727-1742 (2017);Takata, K. et al. Immunity 47, 183-198.e186 (2017);Pandya, H. et al. Nat Neurosci 20, 753-759 (2017);Brownjohn, PW et al. Stem Cell Reports 10, 1294-1307 (2018)); these approaches usually rely on the formation of embryoid bodies, are poorly defined with respect to ontogeny (Muffat, J. et al. Nat Med 22, 1358-1367 (2016);Haenseler, W. et al. Stem Cell Reports 8, 1727-1742 (2017)), require manipulation, e.g., hypoxia for patterning (Abud, EM et al. Neuron 94, 278-293.e279 (2017)), or require cell sorting for purity (Douvaras, P. et al. Stem Cell Reports 8, 1516-1524 (2017)). Importantly, none of the microglial differentiation protocols demonstrate clear patterning towards primary hematopoiesis as defined by induction of KDR+CD235A+ hemangioblasts (Sturgeon, et al. al., Nat Biotechnol 32, 554-561 (2014)). Because microglia are unique in that their lineage is entirely traceable back to primary hematopoiesis, it is important to recapitulate these early developmental steps in vitro (Ginhoux, F. et al. Science 330, 841-845 (2010)).
[0223] To build a fully human platform for studying neuroinflammation, we identified and demonstrated a novel approach for deriving microglia from human pluripotent stem cells (hPSCs), which clearly recapitulates microglial ontogeny, by single-cell RNA sequencing and stage-specific mapping against a dataset of developing mouse microglia. We used these cells to build the first defined fully human avian culture system containing pure populations of hPSC-derived microglia, astrocytes, and neurons for in vitro analysis of cellular crosstalk along the neuroinflammation axis. We generated the avian culture system to investigate inflammation in Alzheimer's disease, as described in the APPSWE study. + / +The study was modeled using syngeneic hPSCs carrying the mutation. Data disclosed herein revealed that production of complement C3, a protein that is increased under inflammatory conditions and implicated in synapse loss, was enhanced under avian culture conditions and further enhanced in APPSWE+ / + avian cultures. Using cell type-specific ablation studies, it was noted that enhanced C3 was due to the existence of a neuroinflammatory loop in which microglia were the key initiators, activating astrocytes to generate excess C3. The work disclosed herein defines the key cellular players that contribute to increased C3 in AD and presents a broadly applicable platform to study neuroinflammation in human disease.
[0224] The strategy disclosed here was designed to differentiate hPSCs into microglial progenitors (Figure 26A). First, cells were treated with the GSK3b inhibitor CHIR99021 (Lindsley et al., Development (2006); 133, 3787-3796) and patterned towards primitive streak mesoderm by activating WNT signaling. WNT inhibition was then induced by the porcupine inhibitor IWP2 and mimicked by simultaneously activating Nodal signaling and exposure to activin A. These conditions biased the generation of KDR+CD235A+ primary hematopoietic hemangioblasts versus KDR+CD235A- secondary hematopoietic progenitors, following the paradigm proposed in (Sturgeon et al., Nature Biotechnol. (2014); 32, 554-561). It was observed that WNT inhibition must occur within a very narrow developmental window restricted to 18 hours after WNT activation to efficiently generate a KDR+CD235A+ population (Figure 26B). After optimizing conditions for cell density and small molecule exposure (see Materials and Methods), 18 hours of WNT activation, followed by 2 days of WNT inhibition and Nodal activation, resulted in approximately 30% KDR+CD235A+ cell death by day 3 of differentiation. + CD235A + The cells are obtained (Figure 26C). + CD235A +It was determined whether hemangioblasts versus KDR+CD235A- secondary progenitors generated hematopoietic cells under these culture conditions. + CD235A + The hemangioblast population expresses CD41 within 3 days after replating (day 6 of hPSC differentiation) in the presence of minimal hematopoietic cytokines. + CD235A + CD43 + It was observed that the KDR cells produced hematopoietic cells (Fig. 26D). + CD235A - The hemangioblast population did not produce hematopoietic cells (Figure 26D). The data disclosed herein demonstrate that secondary progenitors only generated hematopoietic cells at later stages of differentiation under hypoxic conditions or in the presence of additional hematopoietic cytokines. By day 7 after replating, KDR + CD235A + By fraction, 41% were CD45 + The other cell population was uncommitted CD41 cells, which were the population that generated microglia at a later stage. + CD235A + CD43 + Erythroid myeloid precursors (EMPs), CD41 + Megakaryocytes, and CD235A + EMPs, megakaryocytes, and erythrocytes were all lineages produced during primary hematopoiesis (Palis et al., FEBS Lett. (2016); 590, 3965-3974) (Figure 26D). Secondary KDR + CD235A - The population still did not produce hematopoietic cells, indicating that all hematopoietic cells produced by day 10 of differentiation were KDR + CD235A + It was demonstrated that the cells were derived from hemangioblasts. + CD235A - Groups and KDR + CD235A + The unscreened sample, which included both the screened KDR + CD235A+ These results suggest that the KDR + CD235A + This suggests that the cells do not need to be purified for robust production of hematopoietic cells (Figure 26D). This finding simplifies the differentiation process by removing the cell sorting step and instead allowing for simple replating of the mixed population on day 3 in the presence of hematopoietic cytokines. Approximately 60% of the cells at day 10 of differentiation express VE-cadherin + Hematopoietic identity formed floating colonies in semi-suspension on hemogenic endothelial cells (Raffi et al., Blood (2013); 121, 770-780) (Figures 31B and 31C).
[0225] Next, single-cell RNA sequencing experiments were performed at days 6 and 10 of differentiation to fully characterize the cellular heterogeneity and identify the developmental trajectory of the transitional cell state, given the paucity of data for human primary hematopoiesis in the current literature. The differentiation composition and trajectory were compared to those from in vivo mouse development to establish whether the method disclosed here actually produces primary hematopoiesis on a dish. Pooled day 6 and day 10 single cell RNA sequencing data were separated into distinct clusters along trajectories defined after diffusion mapping analysis (Figure 27A). More mature hematopoietic populations of erythrocytes (ERY), megakaryocytes (MK), and macrophage precursors (PMAC) emerged from three distinct arms arising from a common EMP population, mimicking the trajectory of primary hematopoiesis. The differentiation potential of the cells was calculated over pseudotime along the trajectory using the Palantir algorithm (Setty et al., Nat. Biotechnol. (2019); 57, 451-460), the results showed that the highest differentiation potential was in the hemogenic endothelial cluster and EMP-like cells in the center of the map, and the lowest in the more mature hematopoietic clusters at the ends of the three arms (Fig. 27B). Expression of key genes was also calculated over pseudotime along the trajectory of each arm (Fig. 27C). The erythroid arm expressed the signature genes of embryonic hemoglobin (HBE1) and GYPA, the megakaryocyte arm expressed the key megakaryocyte genes of ITGA2B, ITGB3, and GP1BA, and the macrophage precursor arm expressed CSF1R, PTPRC, and CX3CR1 (Kierdorf et al., Nat. Neurosci. (2013); 16, 273-280). Trajectories were isolated along only the macrophage precursor arm and their gene expression was compared to EMP and pre-macrophage (PMAC) gene signatures from in vivo profiling of mouse microglial development (Mass et al., Science (2016); 353) (Figure 27D). At pseudotimes of 0.44-0.8, corresponding to the early EMP and EMP / PMAC clusters, the data disclosed herein were enriched in the mouse EMP signature, and at pseudotimes of 0.84 and above, corresponding to the mature PMAC1 / 2 cluster, the data were enriched in the mouse pMAC signature (Mass et al. Science (2016); 353). However, of the 90 and 51 genes present in the mouse EMP and pMAC signatures, respectively, 81 and 49 genes were present in the scRNAseq dataset disclosed here, and only a subset of these genes were expressed individually in the human EMP or pMAC clusters, with some genes expressed in both (Figure 27D), likely representing differences between humans and mice. We also mapped these data to the entire mouse gastrulation single-cell RNA-sequencing data (Pijuan-Sala et al., Nature (2019); 566, 490-495), and noted that the cluster of hematopoietic cells closely matched with mouse hematopoietic cells. Notably, the PMAC cluster mapped near the mouse gastrulation myeloid cluster (Figure 27E).When compared to data obtained from multiple time points during mouse gastrulation during development, the data disclosed herein contained populations most similar to those that emerged at E8.5, 1 day before microglial progenitor cells were first seeded into the mouse brain (Figure 27F). Collectively, these data demonstrate that the presence of EMPs and EMP-derived pMacs in the cultures disclosed herein closely coincides with mouse myeloid cells during early microglial development, and indicate that the human in vitro culture system disclosed herein follows the hypothesized developmental roadmap for microglial development.
[0226] Two alternative methods were established in this disclosure by which either EMPs or pMacs may be functionally matured into microglia (Figure 28A). In the first method, microglial precursors were seeded into the brain and allowed to develop into microglia within a neural environment, mimicking the in vivo developmental trajectory (Pijuan-Sala et al., Science 2016; 353). To replicate this paradigm, cells in suspension were harvested on day 10 and directly co-cultured with day 30 hPSC-derived cortical neurons in the presence of IL-34 and M-CSF, cytokines important for microglial survival and maturation (Wang et al., Nat. Immunol. (2012);13, 753-760) (Figure 28A, panel i). 50,000 cells in suspension were seeded for every 300,000 cortical neurons, yielding approximately 16% hematopoietic cells per culture at the time of seeding. Notably, within 4 days of coculture, adherent, ramified, microglia-like cells that expressed IBA1 and PU.1 appeared (Fig. 28B). These cells expressed CX3CR1 + GPI was also expressed, constituting more than 30% of the co-cultures, indicating ongoing cell proliferation parallel to differentiation towards the microglial lineage (Figure 28C). To address whether other primary hematopoietic lineages emerge in these co-cultures, GPI - H2B - GFP from hPSC lines + We generated hematopoietic cells (Figures 32A-32B) and co-cultured them with hPSC-derived cortical neurons. On day 6 of co-culture, GFP+ The majority of the cells were CD45+, indicating that they had differentiated along a microglial rather than a megakaryocyte or erythroid trajectory. + 82% of the cells expressed CX3CR1, and the majority expressed CD45 + This suggests that the cells had transitioned to a microglial fate (Figure 28D). + Approximately 10% of cells are CD45 + Half of these cells were immature CD41 + CD235A + EMPs, whereas the other half were negative for these markers, likely indicating an even more primitive hematopoietic lineage. These data demonstrate that co-culturing day 10 EMPs and PMACs with cortical neurons yields a population of microglial cells within 4 days, but that a small population of uncommitted hematopoietic cells may remain.
[0227] A second strategy to mature microglia from the precursor stage was developed to derive a completely pure and synchronized population of microglia (Figure 28A, panel ii). Bulk populations of hematopoietic cells were pooled in suspension on day 10 and subsequently exposed to serum-containing medium (RPMI + 10% serum supplemented with IL-34 and M-CSF) or defined serum-free conditions (IMDM / F12 supplemented with IL-34 and M-CSF) for 7–11 days. At 4 days of culture, half of the cells had transitioned to the primitive macrophage stage, with 50–60% expressing CD11B (a mature macrophage / microglia marker) and CX3CR1 (restricted to tissue-resident macrophages, e.g., microglia). By 11 days of culture, nearly 99% of the cells expressed CD11B and over 85% expressed CX3CR1 (Figure 28E). At this stage, all cells were attached and showed elongated morphology, and PU.1 +(Figures 33A and 33B). In contrast, primary human peripheral blood mononuclear cells (PBMCs) matured in parallel under the same culture conditions expressed CD11B but almost no CX3CR1 expression (Figure 28E). The resulting pure population of primitive macrophages was co-cultured with hPSC-derived cortical neurons to fully transition these cells to a microglial fate. After 4 days of co-culture, microglial cells showed branching and upregulated IBA1 (Figure 28F and Figure 33C). When compared to mature PBMCs co-cultured with neurons, microglia-like cells had low levels of CD45 and maintained expression of CX3CR1, whereas PBMC-derived cells expressed CD45 in the absence of CX3CR1 (Greter et al., Front Immunol. (2015); 6) (Figure 28G). To determine transcriptional identity, hPSC-derived microglial cells were cultured at 2 weeks after the initiation of co-culture with CD45 + We selected the cells using CX3CR1+. We observed expression of signature microglial genes at levels similar to those in human fetal microglia (Butovsky et al., Nat. Neurosci. (2014);17, 131-143; Bennett et al. al., Proc. Natl. Acad. Sci. USA (2016); 113, E1738-1746) (Fig. 28H). Interestingly, TMEM119 and SALL1 were significantly increased during neural coculture (Gosselin et al. al., Science (2017); 356) (Figure 28H). Single-cell RNA sequencing of co-cultured hPSC-derived microglial cells revealed that the cells displayed a homogenous cell population lacking undifferentiated precursors (Figures 34A-34B). The calculated pairwise distances between cells in the microglial samples fell into a clean unimodal distribution, indicating almost no variance between cells (Figure 34A). In contrast, the pairwise distances calculated between cells at 10 days before co-culture showed multiple peaks in the distribution, indicating the heterogeneous character of the cells (Figure 34B). We next determined which of the two derivation methods would yield cells that were more transcriptionally similar to primary human microglia. After 14 days of co-culture with cortical neurons, microglial cells were cultured using CD45 + CX3CR1 + We sorted them using and compared their gene expression to primary adult human microglia via bulk RNA sequencing. After unsupervised hierarchical clustering, both methods yielded microglial cells that clustered with primary human microglia obtained from postmortem cortical brain tissue (frontal and temporal, ages 60-77 years) (Figure 28I). However, neither method yielded microglial cells that strictly fell into the same sub-branch as primary human microglia, possibly due to the age of the cells (embryonic vs. aged) and / or as a result of in vitro culture.
[0228] hPSC-derived microglial cells shared functional similarities with in vivo microglia. hPSC-derived microglial cells co-cultured with neurons were observed to retract and extend their processes to explore their environment, sampling the surrounding neurons similar to homeostatic microglia in vivo (Nimmerjahn et al., Science (2005);308, 1314-1318). When challenged with the yeast-antigen zymosan, the cells were able to perform more efficient phagocytosis compared to astrocyte controls (Wake et al., Neuron Glia Biol (2011); 7, 1-3) (Figure 35A-35B). Finally, another role of microglial cells is to prune synapses in the developing brain (Stevens et al., Cell (2007);131, 1164-1178). When co-cultured with synapsed mature hPSC-derived neurons (D70 and earlier (Figures 36A-36B)), microglial cells displayed inclusions containing synaptic material upon confocal imaging (Figure 28J, panel i). Although inclusions containing general neural material labeled with RFP were present, the number of inclusions specifically composed of synaptic material was 1-2% (Figure 28J, panel ii). This number was consistent with the basal level of synaptic incorporation reported for primary microglial cells during homeostasis (Schafer et al., Neuron (2012); 74, 691-705).
[0229] The ability to generate nearly pure microglia with properties consistent with their primary counterparts within 21 days of differentiation set the stage for constructing a functional, fully hPSC-derived avian culture platform composed of human microglia combined with similarly pure populations of human astrocytes (Tchieu et al., Nat Biotechnol (2019); 37, 267-275) and cortical neurons (Chambers et al., Nat Biotechnol (2009); 27, 275-280;Qi et al., Nat. Biotechnol. (2017); 35, 154-163) (Figure 29A). hPSC-derived astrocytes were generated as recently described (Tchieu et al., Nat Biotechnol (2019); 37, 267-275) and all expressed GFAP+ with a subset expressing AQP4+ (Figure 29B). Similarly, examples disclosed herein that generated pure hPSC-derived neurons were of cortical neuronal identity expressing cortical layer markers TBR1 and CTIP2, and a marker of the telencephalon, FOXG1, were generated (Figures 29C and 29D). The optimal ratio of each cell type for establishing the tri-culture platform was identified as 2:1:8 for initial seeding, with 1 cm 2 The median number of microglia:25,000 astrocytes:200,000 neurons per culture was 50,000 microglia:25,000 astrocytes:200,000 neurons per culture. These conditions allowed robust microglial cell attachment and survival in the presence of astrocytes, as increasing astrocyte numbers interfere with microglial cell attachment (Figure 37A). Basal medium culture conditions in the presence of IL-34 and M-CSF were further optimized to reduce baseline inflammatory cytokine production, focused on complement C3 production (Figure 37B). NB / BAGC (see methods) conditions resulted in very low baseline C3 induction, accompanied by excellent survival and maintenance of neurons (Qi et al., Nat. Biotechnol. (2017); 35, 154-163). After 1 week, the tricultures produced ramified IBA1+ microglial cells and MAP2 +They showed numerous GFAP+ astrocytic processes interacting with cortical neurons (Figure 29E). Tricultures were nearly devoid of any apoptosis, and CC3+ cells demonstrated superior survival of all three cell types (Figure 29F and Figure 37C).
[0230] To test whether the chick culture system could recapitulate the neuroinflammatory axis between microglia, astrocytes, and neurons, we measured the production of complement C3 as a surrogate marker. First, we measured C3 secretion under different co-culture conditions: neurons only (200,000 cells / cm); 2 ), astrocytes and neurons (25,000+200,000 cells / cm 2 ) Microglia and neurons (50,000+200,000 cells / cm 2 ), and triculture (50,000 microglia / cm 2 +25,000 astrocytes / cm 2 +200,000 neurons / cm 2 ) was assessed by ELISA. At baseline, C3 was present only in cultures containing microglia, while C3 levels were extremely low in astrocyte / neuron co-cultures and undetectable in neuron-only cultures. Interestingly, in tri-cultures, baseline C3 levels were dramatically higher than those in microglia / neuron-only cultures, suggesting enhanced C3 secretion via cellular crosstalk in the presence of both microglia and astrocytes (Figure 29G). C3 secretion was measured after stimulating cultures with the inflammatory protein lipopolysaccharide (LPS) to pharmacologically model a neuroinflammatory situation (Chen et al., J. Neurosci. (2012); 32, 11706-11715). After LPS treatment, levels of C3 increased in all cultures containing microglia, but were also greatly enhanced under tri-culture conditions (Figure 29G). To exclude the possibility that such enhancement might simply reflect an increase in microglia numbers, IBA+ cells were quantified by immunofluorescence using high-content imaging microscopy. +Positive cells were actually decreased in avian cultures versus microglia / neuron co-cultures, ruling out increased microglial numbers as the cause of the high C3 levels (Figures 38A and 38B). LPS stimulation induced an inflammatory context that went beyond C3 secretion and increased levels of classical inflammatory cytokines, such as IL-6, TNF, and IL-10 by ELISA (Figure 29H).
[0231] A C3 KOhPSC line was generated using CRISPR / Cas9 that showed a complete lack of C3 production (Figure 29I). This line was differentiated into C3 KO astrocytes and C3 KO microglia, and avian cultures were generated that contained C3 KO astrocytes, wild-type microglia, and neurons (C3KOA) or wild-type astrocytes, C3 KO microglia, and neurons (C3KOM). The number of microglia scored by %IBA1 / DAPI and the number of astrocytes scored by %GFAP / DAPI were similar across wild-type avian, C3KOA, and C3KOM cultures (Figure 38C). At baseline, C3KOA cultures showed reduced C3 levels compared to WT avian cultures, but higher levels than microglia / neuron cultures (Figure 29J). Interestingly, C3 levels were very low in C3KOM cultures, indicating that in order to effectively induce astrocytes to produce C3 in avian cultures, microglia must express C3 (Figure 29J). Whether this microglial C3 acts directly on astrocytes or indirectly through autocrine stimulation of microglia remains to be determined. Comparable results were obtained following LPS stimulation. C3KOA cultures stimulated with LPS show lower C3 levels than WT cultures stimulated with LPS, but higher levels than those of microglia / neuron-only cultures stimulated with LPS. C3KOM cultures stimulated with LPS show very low C3 levels (Figure 29J). These data characterize a cellular crosstalk between microglia and astrocytes in an inflammatory loop that is both present at baseline and exacerbated upon pharmacological induction of a neuroinflammatory context (Figure 29K). In this loop, C3-producing microglia are the initiating cells that signal astrocytes to produce C3. C3KOA results indicate that astrocytes can re-induce microglia to produce more C3.
[0232] Given the ability of the in vitro chicken culture system disclosed here to unravel the cellular components of the neuroinflammatory axis, we applied this platform to model neuroinflammation in the disease context of Alzheimer's disease. + / + Targeted syngeneic human ESC lines containing mutations were used (Paquet et al., Nature 2016; 533, 125-129). Differentiated AD- and syngeneic control hPSC-derived neurons were demonstrated by FOXG1 and MAP2 expression as well as TBR1 and CTIP2 for cortical identity (Figure 30A and Figure 30B). + / + Neurons showed increased amyloid-beta production, a hallmark of the APPSWE model of Alzheimer's disease (Paquet et al., Nature 2016; 533, 125-129) (Fig. 30C). Mature 80-day-old APPSWE + / + Tri-cultures were established by seeding WT differentiated astrocytes (GFAP+) and WT differentiated microglia (IBA1+) in co-cultures with neurons or syngeneic control neurons (Figure 30D). On day 8 of the tri-culture, APPSWE + / + C3 levels were measured by ELISA in avian cultures containing neurons versus those containing syngeneic control neurons. Interestingly, C3 levels were significantly higher in APPSWE compared to those from syngeneic controls. + / + C3 was not produced at high levels or in APPSWE + / + Astrocytes / Neurons and APPSWE + / + There was no increase in neuron-only cultures versus syngeneic control astrocyte / neuron and neuron-only cultures, indicating that microglia must be present in the cultures for robust C3 production.
[0233] APPSWE + / + To determine whether the source of increased C3 in avian cultures was due to astrocytes or microglia, we generated microglia and astrocytes from C3 KO hPSCs and compared them with C3 KO astrocytes, wild-type microglia, and APPSWE. + / + neurons or syngeneic control neurons (C3KOA), or wild-type astrocytes, C3 KO microglia, and APPSWE + / + We generated avian cultures containing neurons or syngeneic control neurons (C3KOM). Notably, significantly reduced C3 levels were observed in C3KOAAD avian cultures, comparable to those in syngeneic control avian cultures (Figure 30F). However, C3KOA AD avian cultures further exhibited increased C3 levels compared to C3KOA syngeneic avian cultures. In C3KOM cultures, the level of C3 production was low, suggesting that APPSWE + / + To induce C3 expression in avian cultures, C3-expressing microglia must be present (FIG. 30F).
[0234] Next, C1Q deposition levels were assessed by Western blot. C1Q is a complement protein upstream of C3 that forms a complex with the cleavage products of complement C3 and also tags synaptic material for clearance (Hong, S. et al. Science (2016); 352, 712-716). Surprisingly, APPSWE + / + Increased C1Q protein was observed in the cultures, and C1Q was only present in cultures containing microglia (Figure 30G). C1Q has been shown to accumulate in vivo in AD (Hong, S. et al. Science (2016); 352, 712-716; Afagh, Exp. Neurol. (1996); 138, 22-32), where we recapitulated this phenotype in an in vitro model of AD. + / +It was noted that C1Q levels were decreased in avian cultures compared to syngeneic control cultures, microglia / neuron, C3KOA, and C3KOM cultures (Figure 30G). This suggests that there may be a negative feedback between C3 levels and C1Q, as cultures with high levels of C3 (avian cultures) exhibited lower levels of C1Q compared to cultures with low levels of C3 (microglia / neuron, C3KOM, C3KOA). However, the exact mechanism for this inverse relationship remains to be determined in future studies.
[0235] Based on the results from the in vitro avian culture system disclosed here, we proposed a model of cellular contribution to neuroinflammation in Alzheimer's disease focusing on complement C3 (Figure 30H). C3 levels in AD were increased compared to syngeneic control avian cultures, and this increase can be interpreted as due to C3 induction of astrocytes by microglia as well as C3 re-induction of microglia by astrocytes. The results suggest that APPSWE, which leads to microglia inducing interactions between both microglia and astrocytes, is a key regulator of AD. + / + An inflammatory loop involving neurons is indicated. Moreover, increased C1Q deposition in AD cultures was detected only in the presence of microglia and was independent of their C3 status.
[0236] The avian culture system disclosed herein allows the analysis of cellular crosstalk through genetic manipulation and allows the study of the mechanism of increased complement C3 production in avian cultures upon LPS stimulation and in AD models, as has been reported in recent literature during aging (Shi et al., J. The focus on C3 was due to its increased expression in inflammatory cells (Neurosci. (2015); 35, 13029-13042) and neurodegenerative disorders, e.g., AD (Wu et al., Cell Rep. (2019); 28, 2111-2123;Rasmussen et al., Alzheimer's Dement. (2018); 14, 1589-1601), and C3 has been implicated in leading to abnormal synaptic pruning (Hong et al., Science (2016); 352, 712-716; Shi et al., Sci. Transl. Med. (2017); 9). However, the technique can be easily adapted to study other disease-associated neuroinflammatory target pathways. Identification of key cellular players contributing to the neuroinflammatory axis in humans should enable the development of directed cell type-specific therapeutic strategies. Indeed, the hPSC-derived avian culture system can serve as a scalable platform for screening therapeutic compounds that specifically target the crosstalk between microglia, astrocytes, and neurons in Alzheimer's disease or other neurodegenerative disorders. material and method Derivation of microglia from hPSCs
[0237] hPSCs maintained in Essential 8 medium were dissociated by Accutase to obtain single cell suspensions. 60,000 cells / cm2 were seeded in E8 medium containing Activin A (R&D338-AC) (7.5 ng / mL), BMP4 (R&D) (30 ng / mL), CHIR 99021 (Tocris) (3 μM), and ROCK inhibitor (Y-27632) (10 μM) on Matrigel-coated plates. After 18 hours, the medium was replaced with Essential 6 medium containing Activin A (10 ng / mL), BMP4 (40 ng / mL), and IWP-2 (Selleck) (2 μM). On day 2, the medium was changed to Essential 6 medium containing Activin A (10 ng / mL), BMP4 (40 ng / mL), IWP-2 (2 μM), and FGF2(R&D) (20 ng / mL). On day 3, the cultures were dissociated with Accutase and plated at 60,000 cells / cm. 2On day 4, the ROCK inhibitor was removed and the medium was replaced with Essential 6 containing VEGF (R&D) (15 ng / mL), FGF2 (5 ng / mL), and ROCK inhibitor (Y-27632) (10 μM). On days 5 and 6, the cultures were supplemented with Essential 6 medium containing VEGF (15 ng / mL), FGF2 (5 ng / mL), SCF (200 ng / mL), and IL-6 (20 ng / mL). On days 7 and 9, the medium was replaced with Essential 6 containing SCF (100 ng / mL), IL-6 (10 ng / mL), TPO (30 ng / mL), and IL-3 (30 ng / mL). On day 10, cells in suspension were harvested and either 1) co-cultured with cortical neurons in neurobasal containing B27, L-glutamine, BDNF, ascorbic acid, GDNF, cAMP, IL-34 (100 ng / mL), and M-CSF (20 ng / mL) for 5 days to allow direct transition to microglia or 2) cultured in RPMI containing 10% FBS, L-glutamine, penicillin / streptavidin, IL-34 (100 ng / mL), and M-CSF (10 ng / mL) for 7-11 days until cells attached and elongated to allow transition to primitive macrophages. For serum-free culture, cells in suspension on day 10 were harvested and cultured for 7–11 days in 75% IMDM, 25% F12 medium containing B27, L-glutamine, and IL-34 (100 ng / mL), and M-CSF (20 ng / mL). The migrated macrophages were then cocultured with cortical neurons with the addition of IL-34 and M-CSF for 7 days to upregulate microglia-specific markers. Cortical Neuron Protocol
[0238] hPSCs were dissociated using Accutase and plated at 200,000 cells / cm. 2Cells were seeded on Matrigel-coated plates in Essential 8 medium containing ROCK inhibitor (Y-27632) (10 μM) at 4°C. Cells were treated with Essential 6 medium containing LDN193189 (100 nM) and SB431542 (10 μM) for 12 days, and XAV939 (2 μM) was added for the first 4 days of differentiation. Cultures were supplemented with N2 medium and B27 supplement at 1:1000 for an additional week to generate neural progenitor cells (NPCs). NPCs were then dissociated and replated on polyornithine / fibronectin / laminin-coated plates and maintained in neurobasal, BDNF, ascorbic acid, GDNF, cAMP, L-glutamine, and B27 supplement for neural differentiation and maturation. Astrocyte Protocol
[0239] hPSCs were differentiated into astrocytes according to Tchieu et al. Briefly, cortical neural stem cells were pulsed with NFIA via an inducible lentiviral construct for 5 days, after which CD44+ precursors were sorted, replated, and maintained in astrocyte induction medium containing N2, HB-EGF (10 ng / mL), and LIF (10 ng / mL) for a minimum of 4 weeks. FACS analysis
[0240] Cells were dissociated with Accutase for 20 min and resuspended in FACS buffer containing 1% BSA, 2 mM EDTA, 30 μg / mL DNAse I and Normocin in PBS. Cells were washed and incubated in sorting buffer containing antibodies for 30 min in the dark on ice at 4 degrees Celsius. Gating and subsequent analysis were performed using FlowJo software. Droplet-based scRNAseq library preparation and sequencing
[0241] Four samples were prepared to perform single cell sequencing on different days of microglial differentiation: "Day 6", the 6th day of differentiation; "Day 10", the 10th day of differentiation; "Day 10 suspension", which contains only cells in suspension on the 10th day of differentiation; and "Microglia", which contains end-stage microglial cells cultured with neurons for 14 days. "Day 6" and "Day 10" samples were prepared by treating the cultures with Accutase for 20 min to obtain a single cell suspension. "Day 10 suspension" was prepared by passing the cells in suspension through a 40 μM filter and staining to obtain a single cell suspension. "Microglia" was prepared by incubating microglia-neuron co-cultures with CX3CR1 + All samples were resuspended at 1000 cells / μL in FACS buffer prior to sequencing. Single cell sequencing was performed using 10× Genomics Chromium Single Cell 3' Library according to the manufacturer's protocol. & Gel bead Kit V2 was used. An input of 8,700 cells was added to each 10× channel. Libraries were sequenced on an Illumina NovaSeq device. Preprocessing of scRNAseq data
[0242] scRNAseq data were processed using the SeQC processing pipeline (Azizi et al., Cell (2018); 174, 1293-1308). SeQC generates a cell x gene count matrix after read alignment, multi-mapping read resolution, cell barcode and UMI correction. SEQC included an initial filtering step to remove 1) putative empty droplets based on the cumulative distribution of molecule counts per barcode, 2) putative apoptotic cells based on >20% of molecules of mitochondrial origin, and (3) low-complexity cells, identified as cells if the detected molecules aligned to a small subset of genes. The cell counts per sample after SEQC processing were: 5253, 4320, 5555, and 4961. Median library sizes were 19, 195, 4039, 10, 126 and 16,716 molecules per cell (day 6, microglia, day 10, and day 10 suspensions, respectively). Counts were normalized to library size by dividing each gene molecule count by the total number of molecules detected in the cell and then multiplying by 10,000 to convert the original counts to transcripts per 10,000. Data were then log-transformed using the natural logarithm and pseudocounts of 1. Data analysis was performed using the Scanpy platform (v1.4) (Wolf et al., Genome Biol. (2018); 19, 15). Cellular filtering
[0243] For each sample, cells were clustered using the PhenoGraph clustering algorithm (Levine et al., Cell (2015); 162, 184-197). Clusters of cells with a low number of detected genes (~200) and low or no mitochondrial RNA content were removed as putative empty droplets. Clusters with high mitochondrial RNA and low number of detected genes were removed as putative dead cells. Three clusters not related to hematopoietic differentiation were removed, including two early mesoderm clusters that expressed low levels of MESP1 and PDGFRA but not KDR, PECAM1, or CDH5, and one cluster belonging to the cardiac lineage expressing NKX2.5 and ISL1. Constructing a Nearest Neighbor Graph
[0244] Principal components were used to calculate the Euclidean distance between cells. An adaptive Gaussian kernel was used to convert the Euclidean distance between the k-nearest neighbors of cells to affinity as described by Haghverdi et al. (Haghverdi et al., Bioinformatics (2015); 31, 2989-2998). By using a Gaussian kernel, the affinity between cells decreases exponentially with their distance, resulting in increased affinity for nearby cells and decreased affinity for distal cells compared to the original Euclidean distance. Furthermore, by using a kernel with width adapted to the cells, differences in density over the region of the data manifold are taken into account. The nearest neighbor graph was used as the basis for force-directed graph layout and diffusion map embedding. Clustering and Force-Directed Graph Layout
[0245] Data from day 6, day 10, and day 10 suspension samples were pooled for trajectory modeling. Principal component analysis was performed on the data and the first 20 principal components were selected for further analysis to reduce noise due to high dropout in scRNAseq (Stegle et al., Nat. Rev. Genet. (2015);16, 133-145). Force-directed graph layouts were calculated using the Force Atlas 2 algorithm based on a 30-nearest neighbor graph of the data constructed as described above (Jacomy et al., PLoS One (2014);9, e98674). Clustering was performed using PhenoGraph with default parameter settings (Levine et al., Cell (2015);162, 184-197). Diffusion map embedding
[0246] To approximate a low-dimensional data manifold representing the differentiation trajectories, a diffusion map embedding was constructed using an adaptive Gaussian kernel-based nearest neighbor graph (k=20, as above) (Haghverdi et al., Bioinformatics (2015); 31, 2989-2998). Diffusion map construction is a nonlinear method to reproduce the low-dimensional structure inherent in high-dimensional observations. The first four diffusion components of the diffusion map were selected for trajectory modeling. The diffusion distances between cells, i.e., the Euglidean distances between cells in the "diffusion map space", were then converted to pseudotemporal distances between individual cells as described by Haghverdi et al. (Haghverdi et al., Nat Methods (2016); 13, 845-848). While distances in standard diffusion maps are associated with length-1 random Markov walks along the edges of an “affinity graph”, diffusion distances in multiscale spaces generalize across random walks of all lengths, thereby better capturing the similarities and distances between cells (Haghverdi et al., Nat. Methods (2016); 13, 845-848). Trajectory characterization
[0247] To further characterize the trajectories, we used Palantir (Setty et al. (Nat. Biotechnol. (2019); 37, 451-460). Palantir is a tool that uses pseudotime distance to identify trajectory endpoints in data of differentiated cells and further measures the entropy in the cell phenotype to measure its plasticity and commitment to a specific cell fate. We used a random cell from a high CDH5, high KDR, and high PECAM1 hemogenic endothelial cell cluster as the input approximate starting cell for the Palantir trajectories. The number of neighbors was set to k=20 and the number of diffusion components was set to 4. For all other parameters, the default settings were used. Calculating genetic trends over pseudotime
[0248] To retrieve expression trends of individual genes over pseudotime, we first imputed the processed count matrix using MAGIC (van Dijk et al., Cell (2018);174, 716-729). MAGIC is a method for removing noise in cell count matrices and filling zeros due to dropout by sharing information across similar cells via data spreading. MAGIC was run with the number of neighbors k=40, random walk length t=6, and further settings of initial conditions. Based on the imputed count matrix, we calculated gene trends using a generalized additive model (GAM) as described by Setty et al. Definition of divergent gene modules
[0249] To identify modules of genes in which one branch was upregulated compared to all other branches and early clusters, differential timed expression analysis was performed between the pMAC clusters ("PMAC1", "PMAC2"), the erythroid clusters ("EARLY ERY", "LATE ERY"), the megakaryocyte cluster ("MK") and the hemogenic endothelial cell clusters ("HE1", "HE2") using MAST (Finak et al., Genome Biol. (2015); 16, 278). Genes with a log2 fold increase of at least 0.25 in the cluster of the branch module compared to each of the other groups (Bonferroni corrected p-value < 0.05) were included in the branch module. Division of divergent gene modules into early and late modules
[0250] For each branch, gene propensities were calculated as described above across pseudotime for all branch module genes. Propensities were calculated from the start of the trajectory to the terminal cell of the module branch under consideration. To identify the "activation point" of each gene, i.e. the point in pseudotime at which the gene starts to increase its expression, the computationally calculated gene propensities were first normalized to the range of expression between 0 and 1. Then, the first point in pseudotime at which the gene propensity showed a slope (first derivative) of 0.8 was calculated: this was considered as the activation point. To divide each gene module into "early genes" (early activated genes) and late genes, the earliest moment in pseudotime (range 0 to 1) at which the cell branches more than 0.025 from the starting branch probability, as identified by Palantir, was identified. At this 3-branch point, the cell starts to differentiate towards one of the three cell fates. Genes that were activated at least 0.3 pseudotimes before the 3-branch were considered early genes (i.e. pseudotime = 0.40 for the myeloid arm). All other genes were considered late. Comparison with mouse gene signature
[0251] For comparison with previously published mouse signatures of EMP and pMac (Mass et al., Science (2016); 353), signature mouse gene names with one-to-one mouse-human orthologs (as defined by Ensembl BioMarts (Kinsella et al., Database (Oxford) (2011)) were translated to human gene names. All other genes were excluded from the analysis. Additionally, genes whose transcripts were not detected in the data disclosed herein were excluded. Heatmaps showing pseudotemporal expression trends of signature genes (Figure 27D and Figure 28I) were based on imputed expression values. Imputed gene expression was normalized for each gene to range between 0 and 1. All cells with a minimum myeloid branching probability of 0.1 were included within the heatmap. Cells were ordered by pseudotemporal order and genes were clustered using centroid clustering. For the macrophage gene signature, cells from the microglia sample were added to the track cells, resulting in an artificial pseudotime of 1.1. Integration into a single-cell mouse embryogenesis atlas
[0252] To integrate the trajectory data into a recently published single-cell transcriptomics atlas of mouse gastrulation and early organogenesis (Pijuan-Sala, B. et al. Nature (2019);566, 490-495), we used data from all cells annotated as blood-endothelial lineages in the dataset (15875 cells). Only genes with one-to-one mouse-human orthologs (as described above) were included in the analysis. To further limit organism-related bias, we restricted the gene set to genes that were highly variable in the reference mouse data. Highly variable genes were selected from the set of genes described by Satija et al. (Satija et al., Nat. Biotechnol. (2015); 33, 495-502). The final number of genes included was 1,356. To perform further batch corrections, we used a fast implementation of the mutual neighbor batch correction (Haghverdi et al., Nat. Biotechnol. (2018)36, 421-427) was used. fastMNN (https: / / rdrr.io / github / LTLA / batchelor / man / fastMNN.html) performs batch correction on a principal component matrix instead of a gene expression matrix. The first 20 principal components of the pooled data were used for batch correction. Batch correction was first performed between samples from within the same time point, followed by batch correction between time points. The order of samples used for fastMNN was: late to early mouse data, then human day 10 and day 10 suspension samples (pooled), and finally day 6 samples. Force-directed graph layouts were calculated as previously described. Graphs of clusters of mouse and human data were constructed using PAGA (Wolf et al. al., Genome Biol. (2019); 20, 59). For force-directed layout of the graph, we used only graph edges with weight 0.2 or greater (Jacomy et al., PLoS One (2014);9, e98679). Immunohistochemistry, Live / Dead Assays, and High Content Imaging
[0253] Cells were fixed in 4% PFA for 10 min at room temperature, permeabilized with 0.1% Triton for 5 min, washed with 0.2% Tween-20 in PBS for 5 min, and blocked with 5% donkey serum in 0.2% Tween-20 in PBS for 30 min. Primary antibodies were diluted in blocking solution and incubated with samples overnight at 4°C. Secondary antibodies (Alexa 488, 555, and 647) were diluted in blocking solution and incubated with samples for 45 min at room temperature. DAPI staining was used to identify cell nuclei. Live / dead assays were performed using CC3 and controls of hPSC-derived cortical neurons incubated with 70% methanol for 30 min. The number of microglial cells in the cultures was quantified using the ImageExpress micro confocal high content imaging system (Chambers et al., Nat. Biotechnol. (2009); 27, 275-280). Fields were photographed at 5x magnification and the entire 96-well culture well was scanned. Imaging the engulfment of synaptic proteins
[0254] Microglia were co-cultured with D70+ neurons on ibidi culture dishes for up to 30 days and image stained with PSD95 and IBA1. Cultures were imaged at 40x magnification on a Leica SP8 confocal microscope equipped with white light laser technology and standard argon lasers (458, 476, 488, 496 and 514 nm). Data were processed and analyzed using Imaris: a surface volume mask was generated in the IBA1 channel, in which a separate mask for the PSD95 channel was generated to determine the volume of PSD95 inclusions / volume of IBA1 in a given Z-stack. Phagocytosis assay and surveyor assay
[0255] For the phagocytosis assay, microglial cells or astrocyte controls were incubated with Alexafluor488-conjugated Zymosan A Bioparticles for 5 h in an Olympus Vivaview fluorescent incubator microscope. For the surveyor assay, microglial cells were infected with a lentiviral construct expressing GFP and co-cultured with D50 cortical neurons for 7 days, then incubated for 16 h in an Olympus Vivaview fluorescent incubator microscope. Time-lapse imaging was compiled at 2 min / frame. RNA sequencing
[0256] 50,000–100,000 hPSC-derived microglia from three different hPSC lines, H1, H9, and iPSC line SA241-1, were sorted from neural co-cultures by CX3CR1+. RNA was extracted using Zymo RNA microKit. RNA from primary human microglia was obtained after sorting post-mortem tissue from frontal and temporal lobes from patients aged 60–77 years. All samples were submitted to the MSKCC Integrated Genomics Core for paired-end SMARTER sequencing and 30–40 million reads. Analysis was performed using a standard pipeline via the MSKCC Bioinformatics core. Chicken culture system and LPS assay
[0257] Cortical neurons were cultured from hPSCs at 150,000 cells / cm on plates coated with polyornithine / fibronectin / laminin. 2 Astrocytes were differentiated in 100% CO and matured in neurobasal containing BDNF, ascorbic acid, GDNF, and cAMP (NB / BAGC) for 50–70 days. Astrocytes differentiated from hPSCs were dissociated using Accutase for 20–30 min and then plated on top of neurons at 25,000 cells / cm. 2hPSCs were seeded at 10000 cells / cm^2 and left to rest in NB / BAGC for 4 days. Microglia differentiated from hPSCs were then dissociated using Accutase for 10 min and then seeded at 50,000 cells / cm^2 on the astrocyte / neuron cultures in NB / BAGC containing IL-34 (100ng / mL) and M-CSF (20ng / mL). The medium was changed every other day with fresh addition of IL-34 and M-CSF. After culturing the avian cultures for a minimum of 7 days, LPS was added to the cultures at 1μg / mL for 72 hours. Culture medium was collected, spun down at 2000 rpm for 5 min, and the supernatant was frozen at -80 degrees Celsius until further analysis. Cytokine ELISA
[0258] Culture supernatants were analyzed using the Millipore Luminex FlexMap 3D system. The supernatants from the + / - LPS assay were also shipped to Eve Technologies for multiplex analysis of 14 inflammatory cytokines using a human high sensitivity T cell discovery array 14plex. CRISPR / Cas9 KO of C3
[0259] PX458 vector was nucleofected into H1hESC. Cells were sorted based on GFP expression and cultured as single cell clones in E8 medium with cloneR supplement. Clones were picked onto duplicate plates and genomic DNA was extracted using Bradley Lysis buffer and proteinase K treatment. A 450bp PCR product was amplified around the gRNA cleavage site. The PCR product was then ligated into the original plasmid and clones were screened for indels by Sanger sequencing. Clones with indels were then picked, expanded, karyotyped, and differentiated into microglia for further validation of defective C3 protein secretion by ELISA. Embodiments of the Presently Disclosed Subject Matter
[0260] From the foregoing description, it will be apparent that changes and modifications may be made to the subject matter disclosed herein to adapt it to various usages and conditions. Such embodiments also fall within the scope of the following claims.
[0261] The recitation of a list of elements in any definition of a variable herein includes the definition of that variable as any single element or combination (or subcombination) of the listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0262] All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each individual patent and publication was specifically and individually indicated to be incorporated by reference. The present invention provides, for example, the following items. (Item 1) 1. An in vitro method for inducing differentiation of a stem cell, comprising: a) contacting stem cells with at least one activator of Wingless (Wnt) signaling for up to about 24 hours; b) contacting the cells with at least one inhibitor of Wnt signaling and at least one pro-hematopoietic cytokine to obtain a population of differentiated cells, wherein the differentiated cells are selected from the group consisting of cells expressing at least one erythromyeloid progenitor (EMP) marker, cells expressing at least one pre-macrophage marker, and combinations thereof; and c) inducing differentiation of said differentiated cells into cells expressing at least one microglial marker. The method includes: (Item 2) c) The method according to item 1, wherein the step of inducing differentiation of the differentiated cells into cells expressing at least one microglial marker comprises culturing the differentiated cells with neurons for at least about 5 days, optionally 4 days. (Item 3) c) the step of inducing differentiation of the differentiated cells into cells expressing at least one microglia marker comprises contacting the differentiated cells with at least one macrophage-promoting cytokine for at least about 5 days; and culturing the cells with neurons for at least about 5 days, optionally culturing the cells with neurons for at least 4 days. (Item 4) 4. The method according to any one of items 1 to 3, wherein said cells are contacted with said at least one activator of Wnt signalling for about 20 hours, optionally for 18 hours. (Item 5) 5. The method according to any one of items 1 to 4, wherein the cells are contacted with the at least one inhibitor of Wnt signalling for at least about 1 day up to about 5 days, optionally for at least 1 day up to 4 days. (Item 6) 6. The method of any one of items 1 to 5, wherein the cells are contacted with the at least one inhibitor of Wnt signaling for at least about 2 days. (Item 7) 7. The method of any one of items 1 to 6, wherein the cells are contacted with the at least one hematopoietic promoting cytokine for at least about 1 day and up to about 10 days, optionally for at least 3 days and up to 11 days. (Item 8) 8. The method of any one of items 3 to 7, wherein the cells are contacted with the at least one macrophage-promoting cytokine for 7 days, 8 days, 9 days, or 11 days. (Item 9) 9. The method according to any one of items 1 to 8, wherein the cells are cultured with the neurons for about 5 days, optionally 4 or 5 days. (Item 10) 10. The method of any one of items 1 to 9, wherein contacting said stem cells with at least one activator of Wnt signaling generates cells expressing at least one mesodermal progenitor marker. (Item 11) 11. The method of claim 10, wherein the at least one mesoderm precursor marker is selected from the group consisting of brachyury, KDR, and combinations thereof. (Item 12) 12. The method of any one of items 1 to 11, wherein contacting said cells with at least one inhibitor of Wnt signaling generates cells expressing at least one primary hematopoietic progenitor marker. (Item 13) 13. The method of claim 12, wherein the at least one primary hematopoietic progenitor marker is selected from the group consisting of KDR, CD235A, and combinations thereof. (Item 14) 14. The method of any one of items 1 to 13, wherein contacting the cells with the at least one hematopoietic promoting cytokine further generates cells expressing at least one erythromyeloid progenitor (EMP) marker. (Item 15) 13. The method of claim 12, wherein the cells are contacted with the at least one hematopoietic promoting cytokine for at least about 1 day up to about 5 days or up to about 10 days to generate cells expressing the at least one EMP marker. (Item 16) 16. The method of item 14 or 15, wherein the at least one EMP marker is selected from the group consisting of Kit, CD41, CD235A, CD43, and combinations thereof. (Item 17) 17. The method of any one of items 14 to 16, wherein the cells expressing at least one EMP marker do not express CD45. (Item 18) 18. The method of any one of items 1 to 17, wherein the at least one pre-macrophage marker is selected from the group consisting of CD45, CSF1R, and combinations thereof. (Item 19) 19. The method of any one of items 1 to 18, wherein cells expressing at least one pre-macrophage marker do not express Kit. (Item 20) 20. The method of any one of items 1 to 19, wherein the at least one microglial marker is selected from the group consisting of CX3CR1, PU.1, CD45, IBA1, P2RY12, TMEM119, SALL1, GPR34, C1QA, CD68, CD45, and combinations thereof. (Item 21) 21. The method of any one of items 3 to 20, wherein the at least one macrophage marker is selected from the group consisting of CD11B, Dectin, CD14, PU.1, CX3CR1, CD45, and combinations thereof. (Item 22) 22. The method according to any one of items 1 to 21, wherein the at least one activator of Wnt signaling reduces glycogen synthase kinase 3β (GSK3β) due to activation of Wnt signaling. (Item 23) 23. The method according to any one of items 1 to 22, wherein the at least one activator of Wnt signaling is selected from the group consisting of CHIR99021, Wnt-1, WNT3A, Wnt4, Wnt5a, WAY-316606, IQ1, QS11, SB-216763, BIO(6-bromoindirubin-3'-oxime), LY2090314, DCA, 2-amino-4-[3,4-(methylenedioxy)benzyl-amino]-6-(3-methoxyphenyl)pyrimidine, (hetero)arylpyrimidine, derivatives thereof, and combinations thereof. (Item 24) 24. The method of any one of items 1 to 23, wherein the at least one activator of Wnt signaling is CHIR99021. (Item 25) 25. The method of any one of items 1 to 24, wherein the at least one inhibitor of Wnt signaling is selected from the group consisting of XAV939, IWP2, DKK1, IWR1, peptides (peptides of Nile et al. (Nile et al Nat Chem Biol. 2018 Jun;14(6):582-590)), porcupine inhibitors, LGK974, C59, ETC-159, Ant1.4Br / Ant1.4Cl, niclosamide, apicularen, bafilomycin, G007-LK, G244-LM, pyrvinium, NSC668036, 2,4-diamino-quinazolines, quercetin, ICG-001, PKF115-584, BC2059, Shizokaol D, derivatives thereof, and combinations thereof. (Item 26) 26. The method of any one of items 1 to 25, wherein the at least one inhibitor of Wnt signaling is IWP2. (Item 27) 27. The method of any one of items 1 to 26, wherein the at least one hematopoietic promoting cytokine is selected from the group consisting of VEGF, FGF, SCF, interleukin, TPO, and combinations thereof. (Item 28) 28. The method of claim 27, wherein the interleukin is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, and combinations thereof. (Item 29) 29. The method of item 27 or 28, wherein the FGF is selected from the group consisting of FGF1, FGF2, FGF3, FGF4, FGF7, FGF8, FGF10, FGF18, and combinations thereof. (Item 30) 30. The method of any one of items 3 to 29, wherein the at least one macrophage-promoting cytokine is selected from the group consisting of M-CSF, IL-34, GM-CSF, IL-3, and combinations thereof. (Item 31) 31. The method according to any one of items 1 to 30, wherein the cells are contacted with the at least one activator of Wnt signalling at a concentration of between about 1 μM and about 6 μM. (Item 32) 32. The method of any one of items 1 to 31, wherein the cells are contacted with the at least one inhibitor of Wnt signaling at a concentration of between about 1 μM and about 10 μM. (Item 33) 33. The method of any one of items 1 to 32, wherein the cells are contacted with the at least one hematopoietic promoting cytokine at a concentration of between about 1 ng / ml and about 50 ng / ml. (Item 34) 34. The method of any one of items 1 to 33, wherein the cells are contacted with the at least one hematopoietic promoting cytokine at a concentration of between about 1 ng / ml and about 400 ng / ml. (Item 35) 35. The method of any one of items 3 to 34, wherein the cells are contacted with the at least one macrophage-promoting cytokine at a concentration of between about 1 ng / ml and about 200 ng / ml. (Item 36) 36. A cell population of in vitro differentiated cells expressing at least one microglial marker, said in vitro differentiated cells being derived from stem cells by the method according to any one of items 1 to 35. (Item 37) A composition comprising the cell population described in item 36. (Item 38) A kit for inducing differentiation of stem cells, comprising: (a) at least one inhibitor of Wnt signaling; (b) at least one activator of Wnt signaling; (c) at least one hematopoietic promoting cytokine; and (d) Neuron Kit including: (Item 39) (e) the kit of item 38, further comprising at least one macrophage-promoting cytokine. (Item 40) 40. The kit of item 38 or 39, further comprising instructions for inducing differentiation of the stem cells into cells expressing at least one microglial marker. (Item 41) A composition comprising a population of in vitro differentiated cells, wherein at least about 50% of the cells in said population express at least one microglial marker, and less than about 25% of the cells in said population express at least one marker selected from the group consisting of stem cell markers, mesoderm progenitor markers, primary hematopoietic progenitor markers, EMP markers, premacrophage markers, and macrophage markers. (Item 42) 1. A method of preventing and / or treating a neurodegenerative disease in a subject, comprising: (a) a population of differentiated microglial cells according to item 36; (b) the composition according to item 37; and (c) The composition according to item 41 The method comprises administering to a subject one of the following: (Item 43) 43. The method of claim 42, wherein the neurodegenerative disease is Alzheimer's disease or amyotrophic lateral sclerosis (ALS). (Item 44) A method for preventing and / or treating a neurodegenerative disease, comprising administering a colony-stimulating factor (CSF) to a subject. (Item 45) 45. The method of claim 44, wherein the CSF is selected from the group consisting of colony-stimulating factor (GM-CSF), M-CSF, and IL-34. (Item 46) 46. The method of claim 45, wherein the CSF is GM-CSF. (Item 47) 47. The method according to any one of items 44 to 46, wherein the neurodegenerative disease is Alzheimer's disease. (Item 48) CSF for use in the prevention and / or treatment of neurodegenerative diseases. (Item 49) Use of CSF for the manufacture of a medicament for preventing and / or treating a neurodegenerative disease. (Item 50) 50. The use according to item 49, wherein the neurodegenerative disease is Alzheimer's disease. (Item 51) 1. A method for screening a therapeutic compound for treating a neurodegenerative disease, comprising: (a) contacting a population of differentiated microglial cells according to item 34 with a test compound, wherein the microglial cells are derived from stem cells obtained from a subject with the neurodegenerative disease; and (b) measuring the functional activity of said microglial cells; A method in which a change in said functional activity of said microglial cells indicates that said test compound is likely capable of treating a neurodegenerative disease. (Item 52) 52. The method of claim 51, wherein the change is a decrease or an increase. (Item 53) 53. The method of item 51 or 52, wherein the functional activity of the microglial cells comprises release of complement C3. (Item 54) 54. The method of claim 53, wherein a decrease in the complement C3 released from the microglial cells indicates that the therapeutic compound is likely capable of treating a neurodegenerative disease. (Item 55) 53. The method of claim 51 or 52, wherein the functional activity of the microglial cells comprises amyloid-beta phagocytosis by the microglial cells. (Item 56) 56. The method of any one of items 51 to 55, wherein the neurodegenerative disease is Alzheimer's disease. (Item 57) 1. A method for screening a therapeutic compound for treating a neurodegenerative disease, comprising: (a) contacting a test compound with a composition comprising differentiated microglial cells, a population of astrocytes, and a population of neurons according to item 34; and (b) measuring neurotoxicity of said neurons; A decrease in said neurotoxicity of said neurons after contact with said test compound indicates that said test compound is likely capable of treating a neurodegenerative disease. (Item 58) 58. The method of claim 57, wherein the neurodegenerative disease is ALS disease. (Item 59) 59. The method of claim 57 or 58, wherein the microglial cells induce reactive astrocytes that induce neurotoxicity against neurons.
Claims
[Claim 1] The invention described in the specification.
Citation Information
Patent Citations
Differentiation of pluripotent stem cells into macrophages
JP2018503375A
